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ABSTRACT 
 
 The physiological effects of natural and synthetic estrogens are mediated by 
estrogen receptor alpha (ERα), and estrogen receptor beta (ERβ).  Within the nucleus of 
target cells, ERα and ERβ serve as ligand-activated transcription factors to stimulate or 
repress the transcription of estrogen receptor regulated genes.  ERα and ERβ may be co-
expressed in estrogen-responsive cells, but may also be differentially expressed in a cell- 
and tissue-specific manner.  In addition, within a given context these two receptors have 
different ligand binding and transcriptional activities.  Taken together, these attributes 
underlie differences in target gene regulation, and overall, different physiological actions 
by ER subtypes.  The work described here is an attempt to understand the roles of ERα 
and ERβ in target tissues (e.g. bone, breast, uterus) including the gene networks and cell 
signaling pathways under ER regulation.  We have also characterized the regulation of 
one of the ER-regulated genes, Carbonic Anhydrase XII, and examined its regulation by 
ERα through use of a conserved distal enhancer.   
The work described here reports the characterization of individual gene regulatory 
actions of ERα and ERβ.  To investigate the individual actions of ERα or ERβ, we 
utilized Affymetrix oligonucleotide arrays to profile transcripts regulated by 17β-
estradiol (E2) in U2OS-ERα and U2OS-ERβ cells.  These cell lines were constructed by 
stable integration of ERα or ERβ into human osteoblast-like U2OS osteosarcoma cells 
and initially characterized for ER subtype expression, E2-binding, and cellular responses 
to E2, including proliferation, motility, and adhesion.  Cells expressing apo-ERα or apo-
ERβ did not show significant alteration in adhesion or proliferation after addition of E2, 
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however there was a significant stimulation of migration in E2-treated ERβ-expressing 
cells.  U2OS-ERα, and U2OS-ERβ cells were treated with 10 nM E2 for 0, 4, 8, 24, and 
48 hours and total RNA was collected and hybridized to Affymetryx U95Av2 GeneChips 
and subjected to a Confidence Score to determine E2-regulated RNAs.  Of the ca. 100 
stimulated or repressed genes identified, some were stimulated by E2 equally through 
ERα and ERβ, whereas others were selectively stimulated via ERα or ERβ.  The E2-
regulated genes showed three distinct temporal patterns of expression over the 48 hour 
time course studied.  Among stimulated genes, ERα-containing cells exhibited a greater 
number of regulated transcripts, and overall magnitude of stimulation was increased as 
compared those regulated by ERβ.  Of the functional categories of the E2-regulated 
genes, most numerous were those encoding cytokines and factors associated with 
immune response, signal transduction, and cell migration and cytoskeleton regulation, 
indicating that E2 can exert effects on multiple pathways in these osteoblast-like cell 
lines.  Of note, E2 up-regulated several genes associated with cell motility selectively via 
ERβ, in keeping with the selective E2 enhancement of the motility of ERβ-containing 
cells. On genes regulated equally by E2 via ERα or ERβ, the phytoestrogen genistein 
preferentially stimulated gene expression via ERβ.  These studies indicate both common 
as well as distinct target genes for these two ERs, and identify many novel genes not 
previously known to be under estrogen regulation.  
We have examined the ER regulation of the Carbonic Anhydrase XII (CA12) 
gene, a gene identified as E2-regulated in the studies described above.  We investigated 
the expression of CA12 and its and regulation of by 17β-estradiol and selective estrogen 
receptor modulators in breast cancer cells, and characterize the ER usage of a distal 
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enhancer necessary for CA12 gene regulation.   We find that CA12 expression is highly 
correlated with ERα expression in human breast tumors. We demonstrate that E2 and 
SERMS increase CA12 mRNA and protein in multiple breast cancer cell types expressing 
ERα, and that CA12 regulation by estrogen is a primary transcriptional response 
mediated by ERα.  By genome-wide chromatin immunoprecipitation (ChIP) and ChIP 
scanning of the CA12 locus, we find E2-occupied ERα is recruited to a distal region 6.1 
kb upstream of the CA12 transcription start site (TSS) in vivo.  We find that E2 treatment 
results in recruitment of RNA polymerase II and steroid receptor coactivators SRC-2 and 
SRC-3 to the CA12 genomic locus and is correlated with increased histone H4 
acetylation.  Mutagenesis of an imperfect estrogen-responsive element within this -6.1kb 
distal enhancer region abolishes estrogen-dependent heterologous reporter activity.  
Chromosome conformation capture (3C) and chromatin immunoprecipitation assays 
demonstrate that this distal enhancer communicates with the transcriptional start site of 
the CA12 gene via intra-chromosomal looping upon hormone treatment. This distal 
enhancer element is observed in the homologous mouse genomic sequence, and the 
expression of the mouse homolog, Car12, is rapidly and robustly stimulated by estradiol 
in the mouse uterus in vivo, suggesting that the ER regulation of CA12 is mechanistically 
and evolutionarily conserved. Our findings highlight the crucial role of ER in regulation 
of the CA12 gene, and provide insight into the transcriptional regulatory mechanism that 
accounts for the strong association of CA12 and ER in human breast cancers. In addition, 
our findings imply that involvement of long distance enhancers in regulation of estrogen-
responsive genes in breast cancer may be more frequent than previously appreciated. 
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 CHAPTER 1 
INTRODUCTION AND SIGNIFICANCE 
 
Estrogen receptors as a window into a transcriptional basis for physiology 
The proper coordination of cell- and tissue-specific responses throughout 
development and normal homeostasis of metazoans is achieved, in part, by the dynamic 
control of gene expression by hormones.  This understanding stems directly from the 
pioneering studies of estrogen action by Jensen, Gorski, and others in the 1950’s and 
1960’s showed that hormonal effects could be elicited through regulation of gene 
expression (1-3).  In mammals, the effects of estrogenic steroid hormones are largely, if 
not exclusively, mediated by two members of the nuclear receptor superfamily, estrogen 
receptor alpha (ERα), and estrogen receptor beta (ERβ).   By binding and activation of 
these receptors, estrogens are potent modulators of the development, homeostasis, and 
pathophysiology of many tissues such as the breast, male and female reproductive tracts, 
adipose, and skeletal, cardiovascular, immune, and central nervous systems (4-8).   
 
Estrogen action and endocrine therapies for breast cancer 
While the diverse actions of estrogens are of great interest, the pathophysiological 
role of estrogen receptors in breast cancer has been an area of intense interest.  Breast 
cancer is the most common malignant diagnosis for women in the United States with 
approximately 190,000 diagnoses and 40,000 deaths estimated in 2009 (9).  
Unfortunately, the etiology of breast cancer is only partially understood, but the influence 
of estrogens on breast tumor growth has been known since the early 20th century.    
1
 Cumulative exposure of estrogens to the breast epithelium underlies the majority of 
known risk factors for breast cancer (10, 11).  Estrogens stimulate proliferation of normal 
mammary cells, providing increased cell mass and opportunities for accrual of gross 
chromosomal aberrations and point mutations (12, 13).  Once tumors are established, 
estrogens appear to stimulate breast cancer cell proliferation in most patients with 
primary breast tumors (11, 14). Preventive and adjuvant therapies targeting the actions of 
estrogens, either by lowering the available amount of endogenous estrogens or blocking 
estrogen receptor action, have contributed to the recent decline in breast cancer mortality 
(8, 15, 16).  The decision to employ these therapies is clearly influenced by the relative 
presence or absence of ERα expression in breast tumor samples (5, 17, 18).  ERα is 
expressed in approximately 70 percent of breast cancers, and unbiased clustering of 
tumor expression profiles reveals ERα expression status to be the foremost factor 
partitioning gene expression profiles (19-21).  Patients with tumors expressing ERα 
generally have a more indolent disease and ERα-expressing tumors are more often well-
differentiated and are associated with other favorable prognostic characteristics (18, 22).  
The expression of well-characterized ERα target genes such as Progesterone Receptor, 
pS2/Trefoil Factor1, and Cathepsin D have been used as markers of estrogen action in 
vivo, and thus surrogates for ERα expression, but their expression alone cannot fully 
predict ERα expression status or response to endocrine therapies.  Regardless, the use of 
RNA expression profiling and next-generation sequencing of individual breast tumors 
continues to evolve, providing better classifications of tumor behavior, a greater number 
of genetic determinants and downstream effectors, thereby providing a more 
sophisticated understanding of treatment decisions (19, 21, 23-28). 
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 Unlike ERα, the roles of the more recently discovered ERβ in breast cancer cells 
are still being uncovered, and ERβ appears to negatively modulate the actions of ERα.  
When co-expressed in the same cell, ERβ appears to negatively influence ERα binding in 
a target gene-specific manner, as well as affect global gene expression profiles and cancer 
cell proliferation.  This is consistent with the relative decline of ERβ:ERα levels with 
disease progression, and is suggestive of an overall dampening effect of ERβ on ERα 
actions (29-35).    
 
Mechanisms of Classical Estrogen Receptor Action in a Target Cell 
ERα and ERβ are prototypic steroid hormone receptors, and like all nuclear 
receptor (NR) superfamily members, are intracellular ligand-regulated transcription 
factors which stimulate and repress expression of target genes by sensing classical 
hormones or other signaling mediators (36-38).   ERα and ERβ share a  modular domain 
structure with variable homologies of the respective domains between the ER subtypes.  
They share high homology between their DNA-binding domains which contain two zinc-
finger motifs (DBD; 95% amino acid identity), and substantial homology between their 
ligand-binding domains (LBD; 56% amino acid identity) (39-43).  The two receptor 
subtypes are expressed differentially in estrogen-target tissues and also differ in their 
abilities to bind certain ligands and activate specific responsive promoters or enhancers, 
suggesting that they may have widely-divergent biological actions in vivo (5, 41, 44). 
In the cell, unliganded ERα largely localizes to the nucleus and is complexed with 
chaperone proteins (45-48).  Upon binding of endogenous hormone (e.g. 17β-estradiol; 
E2), the ER undergoes conformational changes and exhibits protein surfaces allowing for 
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 stable self-dimerization, as well as contact with specific regulatory regions of DNA 
termed estrogen-responsive elements (EREs)  (39, 49).   EREs were classically 
considered to be comprised of perfect or imperfect inverted palindromes of 5’-Pu-
GGTCA-3’ with three intervening nucleotides, however considerable diversity of ER 
binding elements have been described (50-53).  In addition, activated ER may also 
directly bind other DNA-bound proteins which then bind or “tether” ER to chromatin and 
(53-57).  Like other transcriptional regulators, the chromatin-bound ERα serves to recruit 
other transcription factors and RNA polymerase II to target genes in a response element- 
and signal-specific manner to regulate gene expression (38, 58, 59).   
ERα may be able to directly bind members of the general transcription machinery, 
but principally regulates transcription through the dynamic recruitment of coregulator 
protein complexes which may (1) have histone acetyltransferase, methyltransferase, or 
deacetylase activites, (2) act as ATP-dependent nucleosome remodeling proteins, or (3) 
mediate contacts with other coregulators and/or the general transcription machinery  (59-
64).  Ligand-bound ERα recruits these regulatory complexes by presentation of two 
activation domains, denoted as activation function 1 (AF1) and activation function 2 
(AF2) located on the N- and C- terminal portions of the receptor, respectively.   AF1 is 
constitutively active and may act independently or synergistically with AF2 when bound 
with agonist.  Importantly, AF1 is modulated by phosphorylation via growth factor-
mediated signaling cascades (65-67) and the relative strength of AF1 transactivation 
ability is dependent on both the context of coregulator proteins available to partner with 
and the promoter context of the target gene (68-70).  AF2 activity, located in the ligand 
binding domain, is ligand dependent and profoundly influenced by the nature of ligand 
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 bound.  Estrogen-bound ER is able to present a binding surface for coactivators such as 
the p160 family of proteins which have both acetyltransferase activity and serve as 
scaffold proteins for recruitment of other transcription factors such as p300 or CBP, 
DRIP/TRAP complexes, and ultimately the general transcription machinery and RNA 
polymerase II.  Pure anti-estrogenic ligands, often referred to as selective estrogen 
receptor down-regulators (SERDS), such as the synthetic antiestrogen ICI 182,780 put 
the receptor into a conformation which fail to recruit coactivators to gene sites and also 
induce pronounced degradation of the receptor.  Mixed agonist/antagonists like the 
selective estrogen receptor modulators (SERMS) tamoxifen and raloxifene put the 
receptor into a range of conformations which are akin to antiestrogen-bound ER, but 
show a mixed ability to recruit coactivators and corepressors depending on the cell- and 
promoter context (71-74).  Thus, the estrogen receptor dynamically nucleates specific 
transcriptional regulatory complexes and displays a complex pharmacology which is 
influenced by the receptor itself (e.g. subtype, expression level, post-translational 
modifications), the nature of the ligand (agonist, antagonist, SERM, SERD), coregulatory 
effectors such as the type of DNA element bound, and coregulator proteins available for 
binding (38, 68, 71, 74-77). 
 
Estrogen Receptor Biology and Genomic Complexity 
While the biology of the estrogen receptor displays a relatively complex 
pharmacology involving the conformation, post-translational modification and location of 
the receptor, ligand, allosteric DNA response elements, and cofactor recruitment 
described above, this understanding is based on the investigation of relatively few 
5
 examples of known ERα-target genes studied in vitro and even fewer target genes studied 
in vivo.  The wider adoption of technological advances such as microarrays and next-
generation sequencing has allowed the examination of E2-responsive RNAs and ER 
binding sites on a genome-wide scale and has allowed a much greater understanding of 
estrogen receptor actions (53, 78-83).   
 mRNA expression profiling of breast cancer and human osteosarcoma cell lines 
expressing ERα, ERβ, or both subtypes has served to greatly expand our understanding 
of the ‘transcriptome’ under ER control (29, 78, 84-90).  Work from the 
Katzenellenbogen group has demonstrated that in ERα-expressing MCF-7 cells, E2 is 
able to regulate as many as ~1500 transcripts (5% of expressed transcripts), and the 
majority of regulated transcripts are actually down-regulated.  Consistent with E2-
induced proliferation of MCF-7 cells, bioinformatic analysis of biological processes (e.g. 
Gene Ontology) regulated by specific E2-regulated transcripts showed clear up-
regulation of pro-proliferation genes such as growth factors and cell cycle regulators, and 
down-regulation of pro-apoptotic and growth inhibitory factors (78).  When considering 
this work with other research groups, a picture of E2-regulated gene expression emerges.  
In general, E2-stimulated genes appear to be regulated early, within 8 hours, while down-
regulated genes appear to be regulated at later times.  Approximately 20% of all regulated 
transcripts in MCF-7 cells are considered direct targets as shown by co-administration of 
the translational inhibitor cycloheximide (78, 86).  Not surprisingly, there is divergence 
of E2-targets in ERα-expressing cell lines derived from different tissues or cell lineages 
(e.g MCF-7, T47-D, and U2OS-ERα), suggesting that expression programs underlie the 
divergent phenotypes (86, 90, 91).  This also underscores the necessity of different 
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 cofactors (e.g. FOXA1) present within a given cell which influence ER activities (80, 91-
95).  In addition, expression profiling has uncovered the necessity of some DNA bound 
transcription factors such as AP-1 for ER-mediated gene regulation (89, 96).  ERα and 
ERβ appear to regulate a widely diverse set of genes (~70% divergent) when expressed in 
a given cell (29, 31, 84, 85, 87).  Again this highlights the differential abilities of ERα 
and ERβ to recruit requisite cofactors and underscores their different biological effects in 
tissues.  Expression studies have been extended to examine the activities of SERMs, 
which have both agonistic and antagonistic actions within a given cell.  The mixed 
agonist/antagonist trans-hydroxytamoxifen acted as a partial or full agonist for 
approximately 50% of E2-stimulated genes and 75% of down-regulated genes (79, 97).   
Importantly, the identification of ER-regulated genes in these cell-based assays has been 
used to develop an outcome predictor able to define clinically relevant subgroups within 
clinically defined ER+ (21). 
The genome-wide identification of ER binding sites has allowed a refinement of 
the classical ERE, as well as additional genomic sequences associated with, and perhaps 
necessary for, ER binding and activity (53, 80, 81, 89, 91, 94, 95).   We now know that a 
majority of the ER binding sites in enhancers are a considerable distance (>5 kb) from 
known and putative ER-target genes (53, 80, 81, 98).  The concept that distant 
transcription factor binding sites can be physically close to their regulated promoters in 
‘cis’ or ‘trans’ is well-appreciated, but still poorly understood.   In fact, the three-
dimensional organization of genomes has been considered to be both functionally 
important for gene expression and relatively plastic in response to developmental or 
environmental cues (99-102).  The use of so called chromosome conformation capture 
7
 (“3C”) and variants of this technique have suggested mechanisms of intra- and inter-
chromosomal communication between these distal ER-binding enhancers and individual 
ER-regulated genes such as pS2/Trefoil Factor1, GREB1, Progesterone Receptor, and 
Carbonic Anhdrase XII (80, 103-106).   Coupling ChIP and chromatin conformation 
techniques with next-generation sequencing has further advanced the study of enhancers 
and their usage on a genome-wide scale (98, 107-110).  Specifically, the recent 
development of the chromatin interaction analysis by paired-end tag sequencing (ChIA-
PET) has allowed for an unbiased, genome-wide method for detecting protein-based 
chromatin interactions in vivo (98).  This technique has been used to examine both ERα 
binding sites with similar base-pair resolution as existing methods (e.g. ChIP-Seq), as 
well as interrogate the physical proximity of ER binding sites to one another and E2-
regulated genes regardless of genomic distance or position within a chromosome.  The 
work by Cheung and Ruan (98) found that activated ERα is recruited to multiple, often 
distal binding sites which physically communicate with each other in both simple duplex 
and complex looping of intervening chromatin.  ERα-bound loops are associated with 
binding of additional factors (e.g. FOXA1) and RNAPII, and appear to be “anchored” at 
E2-target genes, with intervening non-target genes looped out.    These interactions have 
been proposed to provide a physical partitioning of genes for differential regulation and 
act as centers to provide sufficient local concentrations of necessary factors for 
transcriptional regulation.  It is easy to anticipate that the further advancement of methods 
such as ChIA-PET coupled with cell-based imaging will allow for continued appreciation 
of the ability of estrogen receptors to physically and functionally coordinate genomic 
actions. 
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CHAPTER 2 
TRANSCRIPTIONAL PROFILING OF ESTROGEN-REGULATED GENE 
EXPRESSION VIA ESTROGEN RECEPTOR ALPHA OR ESTROGEN 
RECEPTOR BETA IN HUMAN OSTEOSARCOMA CELLS:  DISTINCT AND 
COMMON TARGET GENES FOR THESE RECEPTORS1 
 
Abstract 
Estrogens exert many important effects in bone, a tissue that contains both 
estrogen receptors alpha and beta (ERα and ERβ).  To compare the actions of these 
receptors, we generated U2OS human osteosarcoma cells stably expressing ERα or ERβ, 
at levels comparable to those in osteoblasts, and we characterized their response to 
estradiol (E2) over time using Affymetrix GeneChip microarrays to determine the 
expression of approximately 12,000 genes, followed by quantitative PCR verification of 
the regulation of selected genes. Of the ca. 100 regulated genes we identified, some were 
stimulated by E2 equally through ERα and ERβ, whereas others were selectively 
stimulated via ERα or ERβ.  The E2-regulated genes showed three distinct temporal 
patterns of expression over the 48 h time course studied.  Of the functional categories of 
the E2-regulated genes, most numerous were those encoding cytokines and factors 
associated with immune response, signal transduction, and cell migration and 
cytoskeleton regulation, indicating that E2 can exert effects on multiple pathways in these 
osteoblast-like cell lines.  Of note, E2 up-regulated several genes associated with cell 
motility selectively via ERβ, in keeping with the selective E2 enhancement of the 
                                                 
1 This work was originally published in Endocrinology 145(7):3473–3486, doi: 10.1210/en.2003-1682 
17
 
 
motility of ERβ-containing cells.  Of genes regulated equally by E2 via ERα or ERβ, the 
phytoestrogen genistein preferentially stimulated gene expression via ERβ.  These studies 
indicate both common as well as distinct target genes for these two ERs, and identify 
many novel genes not previously known to be under estrogen regulation.  
 
Introduction 
Estrogen is a pleiotropic hormone with multiple actions in reproductive tissues 
(such as breast, uterus and ovary) and in many non-reproductive tissues including bone, 
the central nervous system and the cardiovascular system.  In the skeleton, estrogen 
effects range from regulation of bone growth during puberty to bone remodeling in the 
adult [reviewed in (1-4)].  The pivotal role of estrogens in the maintenance of bone tissue 
has long been known from clinical studies where estradiol (E2) deficiency in 
postmenopausal or ovariectomized women caused a rapid loss of trabecular bone; 
moreover, in both men and women, estrogen deficiency is associated with an age-related 
sustained bone loss that can lead to osteoporosis.  Both situations can be reversed by 
hormone replacement therapy (1-4).   
Estrogen exerts its effects on bone and other target tissues by interacting with two 
different members of the nuclear receptor superfamily of hormone-regulated transcription 
factors, named estrogen receptor alpha (ERα) and beta (ERβ) (5-7).  These two receptors 
are encoded by different genes, on human chromosome 6 and 14, respectively.  ERα and 
ERβ have similar modular domain structures and very high amino acid identity in their 
DNA-binding domains (97%), whereas they are more divergent in their N-terminal A/B 
domains (only 18% amino acid identity) and in their ligand-binding domains (59% amino 
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acid identity).  After the binding of hormone to these receptors, the hormone-receptor 
complexes bind to specific sequences on the DNA (EREs, Estrogen Response Elements) 
or interact with other transcription factors without direct ERα or ERβ binding to DNA 
(i.e., at AP-1, Sp1, and other sites) (8-13).  In both cases, liganded-ERs recruit 
coregulator proteins and components of the transcriptional machinery to regulate the 
transcription of target genes (14-16).  Recently, the importance of membrane-initiated 
signaling in the actions of estrogens has been highlighted by studies in vitro and in vivo, 
where membrane/cytoplasmic ERs as well as nuclear ERs seem to be involved in 
regulating E2 action and gene transcription in bone and other target cells (1, 17-19).   
In bone, ERs are present in osteoblasts and chondrocytes, and at somewhat lower 
levels in osteoclasts, bone marrow stromal cells, osteocytes and bone cell precursors (20, 
21).  The levels of ERs in bone are generally about 10-fold lower than in reproductive 
tissues, such as uterus, and their levels can be affected by many parameters including cell 
differentiation state (22-24).  Estrogen seems to act directly on osteoblasts and probably, 
as well, on osteoclasts and precursors of both cell types, and indirectly by regulating 
cytokine production in osteoblasts and bone marrow stromal cells, which in turn affects 
the actions and formation of osteoclasts (1, 25).   
The aims of this study were to determine the effects of E2 on gene expression in a 
human osteoblastic cell line and, via transcriptional profiling, to better understand the 
comparative roles of ERα and ERβ in mediating the effects of this hormone.  In 
particular, our interest was to elucidate whether the two receptors elicit the same and/or 
different transcriptional responses on a range of endogenous cellular genes.  For this 
purpose we have generated U2OS human osteosarcoma cells stably expressing either 
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ERα or ERβ and examined several clonal cell lines containing similar, relatively low, 
physiological levels of functional receptor. Using Affymetrix GeneChip microarrays, 
which allow the examination of >12,000 genes, we observed that the hormone-regulated 
genes divided into three distinct temporal patterns and into several functional categories, 
indicating that E2 exerts effects on multiple regulatory pathways in these cells.  In this 
study, we report the identification of genes that were commonly regulated by E2 through 
ERα and ERβ, as well as some that were preferentially or exclusively regulated by one or 
the other ER subtype, and many novel genes not previously known to be under regulation 
by this hormone.  We discuss the relationship of some of these genes to the biological 
effects of E2 we observed in these cells.   
 
Materials and Methods 
Cell culture 
U2OS human osteosarcoma cells were stably transfected with human ERα 
(encoding amino acids 1–595) or ERβ (encoding amino acids 1–530).  Each ER cDNA 
(26) was subcloned into the pcDNA3.1+ expression vector (Invitrogen, Carlsbad, CA) 
which contains a neomycin resistance gene.  Clones were selected with the antibiotic 
G418 (800 μg/ml) and 20 clones per ER subtype were screened for ER expression and for 
transactivation ability with an estrogen response element containing reporter gene 
(2ERE-tk-CAT).  Four clones of each (denoted as ERα clones 1-4 and ERβ clones 1-4) 
were chosen for further characterization and for the gene expression studies.  The U2OS-
ER cells were routinely grown in Minimal Essential Medium with phenol red (Sigma 
Chemical Co., St. Louis, MO) supplemented with 15% fetal calf serum (Hyclone, Logan, 
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UT), 100 units penicillin/ml, 100 μg streptomycin/ml and 400 μg G418/ml.  Before use 
in experiments, cells were grown in Minimal Essential Medium without phenol red and 
supplemented with 5% charcoal-dextran treated fetal calf serum for at least 4 days before 
the start of E2 treatment.  MCF-7 human breast cancer cells were grown as previously 
described (27).  
Hormone binding and Western immunoblot assays   
Whole cell extracts were prepared in cell lysis buffer (20 mM Tris pH 7.4, 0.5 M 
NaCl, 1 mM DTT, 10% glycerol, 50 μg/ml leupeptin, 50 μg/ml aprotinin, 2.5 μg/ml 
pepstatin A, and 0.2 mM phenylmethylsulfonyl fluoride) using freeze/thaw procedure.  
Total protein concentration was determined using the BCA kit (Pierce Biotechnology, 
Rockford, IL).  Whole cell extracts were incubated in duplicate with a range of 3H-E2 
concentrations alone or with 100-fold excess unlabeled E2 for 1 h on ice.  
Hydroxylapatite (HAP) slurry was added and incubated for an additional 15 min on ice.  
The slurry was washed twice and its radioactivity then determined by scintillation 
counting.  The amount of E2 binding in pmol was calculated per mg protein.  
Western blots of whole cell extracts used the ERα specific antibody H222 and the 
ERβ specific antibody UCG40 (kindly provided by Geoffrey L. Greene, University of 
Chicago) and were done as previously described (28).  
Hormone treatments, DNA microarrays, and analysis of microarray data 
U2OS-ERα or ERβ containing cells were maintained in culture for 48 h prior to 
cell harvest and RNA collection.  During this period, cells were treated with 10 nM E2 
(Sigma Chemical Co., St. Louis, MO) for 4, 8, 24 or 48 h, and three separate samples 
were collected for each time point.  Control cell samples were also treated with 0.1% 
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ethanol control vehicle for 48 h.  In this way, cell density was similar in all samples, 
consistent with our observations (as discussed in Results), that E2 does not affect 
proliferation of these cells.  Additional independent time course experiments were 
conducted to generate RNA samples for quantitative RT-PCR verification of gene 
regulation, as detailed in the next section below.  Total RNA was prepared using Trizol 
Reagent (Invitrogen, Carlsbad, CA) according to the manufacturer’s instructions.  RNA 
was further purified using RNeasy columns (Qiagen, Valencia, CA) and treatment with 
RNase free-DNase I (Qiagen, Valencia, CA).   
Total RNA from each sample was used to generate cRNA, which was labeled 
with biotin as recommended by Affymetrix (Santa Clara, CA).  Each cRNA was then 
hybridized on an Affymetrix human Hu-U95A GeneChip, which contains oligonucleotide 
probe sets representing approximately 12,500 human genes and ESTs.  After washing, 
the chips were scanned and analyzed using MicroArray Suite 5.0 software (Affymetrix, 
Santa Clara, CA).  Average intensities for each GeneChip were globally scaled to a target 
intensity of 150.  Data were then analyzed using GeneSpring version 5.0.1 software 
(Silicon Genetics, San Carlos, CA). Data were first normalized on a per chip basis by 
dividing each measurement by the 50th percentile of all measurements on that chip, and 
then E2-treated samples were normalized to the mean of the vehicle treated control 
samples. 
We applied a confidence score (CS) to evaluate which genes were estrogen-
regulated (as described in (29); adapted from (30)).  The CS is based on four parameters: 
fold change (FC), p-value (PV), percentage of present calls (PC) and expression level 
(EL), (CS=FC+PV+PC+EL).  For each parameter, arbitrary scores were assigned.  For 
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fold change, a score of 5 was assigned if the fold change was greater than 1.95, 2 if the 
fold change was between 1.5 and 1.95 and a penalty of –0.5 if it was under 1.5.  For p 
value, a score of 3 was assigned if p-value was less than 0.05, 2 if was between 0.05 and 
0.1, and a penalty of –0.5 if it was greater than 0.1.  If present calls were assigned to more 
than 50% of the samples the score was 3, between 25-50% was 1, and if less than 25% a 
penalty of –0.5 was applied. For the expression level, a score of 3 was applied if it was 
greater than 30, a score of 1 if it was between 15 and 30 and a penalty of –0.5 if 
expression level was less than 15.  The confidence scores ranged from –2 to 14, and 
genes with a CS value of 11 or higher were considered to be significantly E2-regulated 
genes.  To determine ERα or ERβ preference in gene regulation, the average fold change 
for one of the receptors had to be 2.0 or greater, whereas fold change was less than 1.3-
fold for the other receptor at all time points.   
Estrogen-regulated genes were assigned to functional categories according to 
LocusLink, OMIM, PubMed (www.ncbi.nlm.nih.gov), GeneCards 
(bioinfo.weizmann.ac.il/cards) and GenMAPP databases.  The entire microarray data set 
will be available through the Gene Expression Omnibus (GEO 
[http://www.ncbi.nlm.nih.gov/geo]).  
Quantitative real-time PCR  
Real-time PCR was carried out on ca. 25 genes to verify E2 regulation as assessed 
by microarray data analysis, and to evaluate mRNA levels of ERα or ERβ in U2OS 
stably transfected cells.  Three independent time-course experiments using 3 separate cell 
samples each for ERα or ERβ containing cells either E2 or control vehicle treated at each 
time point, were conducted.  The primers used are listed in Table 2.1.  One μg of total 
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RNA from each sample was reverse transcribed in a total volume of 20 μl using 200 U 
reverse transcriptase, 50 pmol random hexamers and 1 mM dNTPs (New England 
Biolabs, Beverly, MA).  The resulting cDNA was then diluted to a total volume of 100 μl.  
Each real-time PCR reaction consisted of 5 μl of diluted RT product, 1x SYBR Green 
PCR Master Mix (Applied Biosystems, Foster City, CA), and 50 nM of forward and 
reverse primers.  Reactions were carried out in an ABI Prism 7700 Sequence Detection 
System (Applied Biosystems) for 40 cycles (95 °C for 15 sec, 60 °C for 1 min) following 
an initial 10 min incubation at 95°C.  The fold change in expression was calculated using 
the ∆∆ Ct comparative threshold cycle method (31) with the ribosomal protein 36B4 
mRNA as an internal control.  As described in (31), gene expression is normalized to an 
endogenous reference gene (36B4) and the fold change in gene expression is then 
determined relative to the vehicle treated control.  
Cell motility and cell adhesion assays   
Cell motility assays used 48-well Boyden microchemotaxis chambers according to 
the manufacturer’s instructions (Neuroprobe, Cabin John, MD).  Briefly, the cells were 
grown in 5% CD-FCS MEM medium without phenol red for at least 4 days until ~70-
80% confluency.  Cells were treated for either 24 h or 48 h with E2 or control (0.1%) 
ethanol vehicle, harvested, and 50 μl of cell suspension (105 cells/50 µl serum-free MEM- 
minus phenol red and containing 0.5% BSA) were placed in the open-bottom wells of the 
upper compartment.  Each pair of wells was separated by a poly-vinylpyrrolidone-free 
polycarbonate porous membrane (8 µm pores) precoated with gelatin (0.2 mg/ml in PBS).  
28 μl of the chemoattractant (MEM with 5% FBS, and MEM with no FBS as control) 
were placed into the lower compartment wells of the chamber.  The Boyden chambers 
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were then incubated for 5 h at 37°C.  Cells were then fixed on the membrane with 
methanol, stained with Diff-Quick staining kit (Baxter Health Corp., McGraw Park, IL), 
mounted onto glass slides, and counted under a 100x microscope objective.   
Cell adhesion assays were performed in 96-well plates coated for 2 h at 37°C with 
20-40 μg/ml of different coating substrates (poly-L-lysine, BSA, collagen type I, 
fibronectin, or laminin).  Cells were treated with 10 nM E2 for 24 or 48 h, and after 
blocking non-specific sites with 1% BSA for 2 h at 37°C, cells were harvested, 
resuspended in MEM minus phenol red containing 0.1% BSA at 105 cells/ml, and 100 μl 
of cell suspension was seeded per well.  Cells were allowed to adhere for 30 min and then 
the medium was gently removed, the wells washed once with MEM minus phenol red 
and the cells then fixed with methanol.  Cells were stained with 0.1% crystal violet for 30 
min at room temperature and washed multiple times with double distilled water.  Stain 
was then extracted from the cells with 5% TritonX-100 overnight at room temperature 
and absorbance monitored at 570 nm.  
 
Results 
Generation and characterization of U2OS cell lines stably expressing ERα or ERβ 
U2OS human osteosarcoma cells, an ER-negative osteoblast-like cell line, were 
stably transfected with either ERα or ERβ using a pcDNA3.1+ plasmid containing a 
neomycin resistance gene as a vector for stable integration.  Positive clones were selected 
with G418 (800 μg/ml), and after two rounds of selection, various clones were tested for 
the presence of ER mRNA by real time PCR and for ER protein by Western blot with 
ERα-specific or ERβ-specific antibodies (Fig. 2.1).  The levels of ERα and ERβ mRNA 
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in U2OS-ER cell clones, as determined by real-time quantitative PCR using standard 
curves with known amounts of ERα and ERβ cDNA (Fig. 2.1A), were compared with the 
parental U2OS cells and with the ERα-containing human breast cancer cell line MCF-7.  
In the eight clones (ERα 1-4, ERβ 1-4) used for most of the studies reported in this paper, 
the number of copies of ERα and ERβ mRNA were similar: 8410±777 per 10 ng total 
RNA for ERα and 9112±1304 for ERβ.  These ERα mRNA levels are ca. 20% of that 
measured in our MCF-7 breast cancer cells.  In addition, as seen in Fig. 2.1A, no ERβ 
mRNA was detected in the ERα-expressing U2OS cells and likewise no ERα mRNA 
was present in the U2OS ERβ-expressing cells.  The parental U2OS cells lacked 
detectable levels of either receptor mRNA.   
Hormone binding (Scatchard) assays were performed on extracts from ERα clone 
1 and ERβ clone 1 cells to ensure the presence of receptor able to bind hormone. These 
assays demonstrated similar levels of 3H-E2 binding in these U2OS-ERα and U2OS-ERβ 
cells (~0.1 pmol/mg protein, Fig.2.1B).  These levels are about 20% of that found in 
MCF-7 cells.  Western blots (Fig. 2.1C) with H222 monoclonal antibody for ERα and 
UCG40 polyclonal antibody for ERβ showed ERα or ERβ of the correct size (ca. 65 and 
56 kDa, respectively), and the presence of only ERβ in the ERβ clones (β clones 1-4 
shown) and only ERα in the ERα clones (α clone 1 shown).  Further characterization by 
estrogen responsive ERE-tk-CAT reporter assays demonstrated that U2OS-ERα and ERβ 
cells possessed E2-dependent transcriptionally functional receptors (data not shown).  
The level of ERα and ERβ in these clones is consistent with previous reports indicating 
the ca. 10-fold lower ER level in bone versus uterine tissue (23, 24).  
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We examined whether E2 affected the motility and adhesion properties of the 
U2OS-ERα and ERβ-containing cells.  Motility was assessed using a Boyden chamber 
chemotactic assay and 5% FBS as a general chemotactic stimulus.  With E2 treatment for 
24 or 48 h, the ERβ-containing cells showed a 3-fold increase in motility; in contrast, 
although the ERα and ERβ-containing cells showed similar motility, E2 elicited no 
change in motility of the ERα-containing cells (Fig. 2.1D).  We also evaluated whether 
E2 treatment for 24 or 48 h affected the adhesive properties of these cells, and found that 
it did not.  An adhesion assay was employed that allows a comparison of the rapid 
adhesion (in 30 min) of the cells to various substrates (poly-L-lysine, BSA, collagen type 
I, fibronectin, or laminin).  Adhesion to collagen type I is shown as an example (Fig. 
2.1E), since it is a major component of bone matrix, and it is seen that E2 had no effect 
on the adhesion of the cells.  This was the case with all of the substrates tested, indicating 
that this property is largely E2-independent.   
Gene expression profiling and time courses of gene regulation using Affymetrix 
GeneChip microarrays 
To characterize changes in gene expression in response to E2 treatment, U2OS-
ERα (clone 1) and U2OS-ERβ (clone 1) cells were treated with 10 nM E2 for times from 
0 to 48 h, and RNA was harvested, purified, and derivatized for gene profiling.  
Affymetrix Hu-U95A GeneChips, which contain probes for approximately 12,000 human 
genes, were used.  As described in Materials and Methods, a confidence score (CS) was 
applied to discriminate genes robustly and reproducibly regulated by E2.  The CS takes 
into account several parameters for each gene and weights the fold change increase or 
decrease versus control, the reproducibility of the output (p-value), the expression level 
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related to the intensity of the signal on the chip and a fidelity score based on a decision 
matrix which compares hybridization of the perfect match probes versus the mismatch for 
each probe set.   
We considered E2-regulated genes to be those with a confidence score equal to or 
greater than 11 (out of a maximum score of 14), and we included in our further studies 
only genes up- or down-regulated more than 2 fold.  Using these criteria, we identified 
105 genes that were E2-regulated through ERα and/or ERβ. This list of genes was 
subjected to gene tree cluster analysis using a standard correlation algorithm available in 
the GeneSpring software.   
In the gene cluster analysis (Fig. 2.2), up-regulated genes are shown in red, down-
regulated genes in blue and unchanging genes in yellow. We observed that many more 
genes were stimulated than inhibited (85 vs 20) in ERα- or ERβ-containing cells, and in 
further analyses, we focused on the up-regulated genes, since these were more numerous, 
were the most robustly regulated and gave good reproducibility of validation by real-time 
PCR.   
When the E2-regulated genes were categorized according to their time patterns of 
expression, three major groupings were identified: early (stimulated only at 4-8 h), early 
and late (stimulated from 4 through 48 h) and late (stimulated only at 24-48 h) (Fig. 2.3).  
For ERα-containing cells, the early and late pattern was the most frequently represented 
(49% of E2-stimulated genes through ERα), followed by the late (46%) and early (5%) 
patterns.  In U2OS-ERβ cells, the distribution was slightly different with 43%, 41% and 
16%, respectively, in these three time patterns.   
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Of the 85 up-regulated genes, 52 were commonly regulated by ERα and ERβ (Fig. 
2.4 top).  These genes, their functions, and their time patterns of regulation are listed in 
Table 2.2.  As shown in Fig. 2.4 top, 24 genes were stimulated selectively by ERα, 
whereas 9 genes were stimulated selectively by ERβ.  Thus, the two receptors showed 
substantial overlap in regulated genes (61% of the genes), but both also have some 
different target genes. The estrogen-stimulated genes regulated selectively through one of 
the two ER subtypes are listed in Table 2.3, along with their temporal pattern of 
regulation and their function.  Many new E2 target genes were also identified, as 
indicated in Tables 2.2 and 2.3.   
Of note, our method of analysis demonstrated E2 regulation of some known E2-
target genes (i.e. pS2/TFF1, PDZK1, GREB1, WISP2, keratin 19, angiotensinogen, 
NHERF/SLC9A3R2, BMP6, connexin 43/GJA1), suggesting the validity of our analyses.  
Further, regulation of several bone-related factors (BMP6, CD34, CD164, PTHLH) by 
E2 was observed (Tables 2.2 and 2.3).   
Functional classification of E2-regulated genes 
To classify E2 up-regulated genes into functional groups (Fig. 2.4) we chose eight 
categories: cytokines/immune response, signal transduction, cell motility/cytoskeleton 
regulation, growth factors/hormones, apoptosis/cell proliferation, housekeeping, nucleic 
acid processing, and other/unknown.  We then assigned each gene to one major category 
representing its primary function (even though many genes encode proteins that have 
several physiological functions), based on mining of several databases (LocusLink, 
PubMed, GeneCards, OMIM, GenMapp).   
29
 
 
Many of the genes commonly regulated through ERα and ERβ encode proteins 
associated with cytokine/immune response, signal transduction, and cell motility and 
cytoskeleton regulation (56% of all genes). Several ERα-selective genes were associated 
with nucleic acid processing.  Very few genes regulated by the ERs were related to cell 
cycle, proliferation or apoptosis, supporting our observations (not shown) that E2 had no 
effect on the proliferation rate of these cells.   
Hormone-regulated genes encoding cytokines and factors associated with immune 
response 
Three members of the Natural Killer cell lectin-type receptors (NKG family), 
NKG2-C, -E and –F (KLRC2, KLRC3 and KLRC4) were robustly regulated by E2 
through both receptors (Table 2.2).  NKGs are activating receptors of natural killer cells 
that mediate HLA-E recognition (32-34).  CD34 (common to both ERα and ERβ up-
regulation, Table 2.2) and sialomucin/CD164 (ERα selective, Table 2.3) are cell surface 
antigens characteristic of human hematopoietic progenitors.  CD164 is an adhesion 
receptor that inhibits proliferation of CD34+ hematopoietic progenitors (35, 36).  
Interleukin-8 (IL-8), a cytokine known for its angiogenic and chemotactic properties, is 
thought to be involved in bone cell function under interleukin-1β and TNFα control in 
bone marrow stromal cells and osteoblasts (37, 38).  It was also regulated by E2 in both 
ERα and ERβ containing U2OS cells (Table 2.2).   
Cyclooxygenase-2 (Cox-2), a key enzyme regulating the production of 
prostaglandins, and also regulating angiogenesis, tumor cell invasion and inflammatory 
responses (39), was markedly up-regulated by E2 via both ERα and ERβ (Table 2.2).  
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Cox-2 has been shown recently to be under estrogenic regulation mediated through the 
PI3K/Akt pathway (40).  
Hormone regulated genes associated with cell motility and cytoskeletal function 
This category is of particular interest because, using cell motility assays, we 
observed an increase in motility of U2OS-ERβ containing cells after E2 treatment (Fig. 
2.1D).  Among the ERβ selectively regulated genes, there are two candidates that might 
be involved in this response.  The first is autotaxin (ENPP2), a known tumor autocrine 
motility factor that has been shown to stimulate the migration of melanoma cells via a G 
protein-coupled phosphoinositide 3-kinaseγ and Cdc42 and Rac1-dependent pathway.  
This regulation possibly involves Paxillin and FAK (focal adhesion kinase), two key 
players in cell adhesion and motility control (41, 42).  Autotaxin has 5-nucleotide 
pyrophosphatase and phosphodiesterase activity, and it acts in the extracellular space as a 
lysophospholipase D with production of lysophosphatidic acid (LPA), which seems to be 
the tumor cell motility inducer (43).  The experiments described in the section below 
demonstrate that autotaxin is very selectively regulated by ERβ.  Another candidate 
associated with the motility increase by ERβ might be Rap1GEF (GFR), a guanine 
nucleotide exchange factor that constitutively activates Rap1 (44) and has been shown to 
be involved in cell motility by modulating integrin function (45, 46).   
Quantitative real-time PCR validation and verification of gene expression regulation in 
multiple cell clones and using ER subtype-selective ligands 
 Table 2.1 shows the primers used, and Tables 2.2 and 2.3 show the ca. 25 genes 
that we verified for their E2 regulation by quantitative PCR (names in italics).  It is of 
note that many of these are genes newly identified as being regulated by E2.  In addition, 
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we verified their E2 regulation in several clones (4 each) of U2OS ERα and/or ERβ-
containing cells (clones 1-4) and used ER subtype-selective ligands to confirm common 
regulation by both ERs or selective gene regulation by ERα or ERβ.  The Tables indicate 
generally good correspondence in gene regulation between the microarray and the 
quantitative RT-PCR analyses using several ERα- or ERβ-containing cell clones.  RT-
PCR, however, is often more sensitive, with a greater dynamic range, such that fold 
changes found by RT-PCR were often greater than those obtained from microarray 
analysis.  
 Figure 5 shows real-time PCR validation of some genes that were commonly 
regulated by E2 through both ER subtypes.  The time course of stimulation for four of 
these genes (GREB1, oligophrenin-1, interleukin-24 and carbonic anhydrase XII) is 
presented.  All of these genes showed up-regulation by E2 by 4 h.  There were robust, 
and very similar fold changes in mRNA for GREB1 mediated via ERα or ERβ over time 
(Fig. 2.5).  Oligophrenin-1 also showed a pattern of mRNA change that was similar for 
ERα and ERβ in which a plateau in stimulation was achieved by 4 h for ERα and 8 h for 
ERβ.  Interestingly, IL-24 was preferentially up-regulated by ERα, with ERβ being a 
much less effective mediating receptor. In contrast, the stimulation via ERβ was 
substantially greater for the carbonic anhydrase XII gene than was the stimulation via 
ERα.  The ER mediation of all of these E2-induced changes is clearly suggested by the 
fact that the stimulation is fully reversed by an excess of the antiestrogen ICI182,780.  In 
addition, and as expected, no stimulation was observed with this pure antiestrogen alone 
(Fig. 2.5).  
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 Figure 2.6 shows the time course changes for two genes selectively regulated 
through ERβ, autotaxin and cystatin D.  Their expression was highly stimulated via ERβ, 
with no significant change being elicited via ERα. The ICI antiestrogen reversal of the E2 
stimulation of these genes supports the mediation by ER (Fig. 2.6).   
 To further examine the selectivity of gene regulation via ERα or ERβ, cells were 
treated with the ERα-selective ligand propylpyrazoletriol (PPT; (47-50)), the ERβ-
selective ligand diarylpropionitrile (DPN; (51, 52)), or the soy phytoestrogen genistein 
which has a higher affinity for ERβ than ERα (53) (Fig. 2.7).  The PDZK1 gene, which is 
equivalently stimulated by E2 via ERα or ERβ, showed stimulation by PPT in the ERα-
containing cells and by DPN in the ERβ-containing cells, as expected.  Interestingly, 
genistein, which has preferential binding affinity for ERβ (53), was considerably more 
effective in stimulating PDZK1 gene expression via ERβ (Fig. 2.7). At the cystatin D 
gene, E2 exclusively stimulated via ERβ, and the stimulation by genistein and DPN was 
only observed in the ERβ-containing cells, with no stimulation by PPT or genistein via 
ERα.  These findings confirm the common regulation of PDZK1 through ERα and ERβ 
observed with E2, and the ERβ selectivity for E2 regulation of cystatin D expression.   
 
Discussion 
 Estrogens exert profound effects on bone, a tissue that expresses ERα and ERβ.  
Yet the individual contributions of ERα and ERβ to gene regulation and physiological 
function in bone remain only partially understood.  In this study, we have characterized a 
model system for examining the actions of the ER subtypes, ERα and ERβ, in a human 
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osteoblast-like cell type.  These studies have enabled us to evaluate changes in the 
expression of ca. 12,000 genes by estradiol through ERα and/or ERβ.  We have 
identified novel estrogen-regulated genes and genes regulated commonly as well as 
exclusively or preferentially through ERα or ERβ.  Further, the identification of 
regulated genes allows some insight into the pathways and gene networks regulated by 
E2 through these two ERs.  
Estrogen regulation of genes associated with cytokines, motility, cytoskeleton, and bone 
remodeling 
 Because estrogen plays important roles in bone remodeling and the control of 
osteoblast and osteoclast numbers (1), it is of note that E2 showed significant regulation 
of cytokines and of genes encoding proteins associated with regulation of the immune 
response.  Our findings are consistent with the reports of estrogen regulation of genes 
encoding cytokines, growth factors and bone matrix proteins in wild type mouse 
trabecular bone and the importance of ERα and/or ERβ in the mediation of these effects, 
as evidenced by the use of ER knockout mice (54-56).  We observed E2 up-regulation of 
genes encoding three members of the Natural Killer cell lectin-type receptors (NKG 
family, KLRC2, KLRC3 and KLRC4).  These NKG family genes were all regulated by 
E2 at early as well as later times.  Other factors associated with cytokine/immune 
function observed to be under estrogen regulation included CD34 antigen, defensin β1, 
IL13 receptor α2, interleukin 8, phospholipase A2, selenoprotein P1, and 
sialomucin/CD164.  Many of these genes, as indicated in Tables 2.2 and 2.3, represent 
new E2-regulated genes not previously reported to be regulated by this hormone.   
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 Another category of genes in which many members were regulated by E2, were 
those associated with regulation of cell motility and the cytoskeleton.  We observed a 
three-fold increase in the motility of the ERβ-containing cells in response to E2 treatment.  
Hence, it is of note that two genes preferentially regulated by E2 via ERβ were autotaxin 
(ENPP2), a known tumor autocrine motility factor and phosphodiesterase, and Rap1 GEF, 
the guanine nucleotide exchange factor that constitutively activates Rap1 and is known to 
modulate integrin function (45, 46).  
 WISP-2, a connective tissue growth factor isolated from osteoblasts (57), was 
regulated by E2 via both receptor subtypes, and it might play a role in cytoskeletal 
regulation in these U2OS cells.  Its stimulation by E2 has been reported in MCF-7 breast 
cancer cells (29, 58).  In addition, oligophrenin-1, keratin 19, integrin α 6, cyritestin 1, 
connexin 43, and cadherin 19, all of which play roles in cell motility and the cytoskeleton, 
were for the most part not previously known to be regulated by estrogen in bone, 
although several are known to be under estrogen regulation in reproductive target cells 
(59, 60). 
 Bone morphogenetic protein 6 (BMP6), a potent osteogenic factor believed to 
play an important role in the bone-protective actions of estrogens, was observed to be up-
regulated through both ERs, as was parathyroid hormone-like hormone (PTHLH/PTHrP), 
a homolog of PTH that functions as an autocrine growth inhibitor for osteoblast-like cells 
and as an anabolic agent in osteoporosis (61, 62).  Neurotensin was another growth 
factor/hormone found to be up-regulated by E2 via ERα and ERβ.  Cystatin D, an E2-
responsive gene newly identified in these studies, was stimulated very preferentially via 
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ERβ.  As this gene encodes a protein that is a secreted inhibitor of cysteine peptidases 
(cathepsins S and H), it might function in several roles in bone physiology.  
ER regulation of other cellular functions: similarities and differences in estrogen target 
genes and temporal patterns of gene regulation in osteosarcoma and breast cancer cells 
 Estradiol up-regulated the expression of several genes encoding proteins 
associated with nucleic acid processing, such as the estrogen receptor coregulators 
RIP140 and TRAP240.  However, in these U2OS cells, E2 regulated very few genes 
associated with apoptosis or cell proliferation, consistent with our findings that E2 had no 
effect on the proliferation rate of either the ERα or ERβ-containing U2OS cells (data not 
shown).  In contrast, in a recently reported study in ER-positive human breast cancer cells, 
in which E2 stimulates cell proliferation, we observed that E2 stimulated the expression 
of positive proliferation regulators including multiple growth factors and genes involved 
in cell cycle progression, and E2 also down-regulated transcriptional repressors and anti-
proliferative and pro-apoptotic genes (29).  Hence, the categories of genes stimulated by 
E2 in the U2OS cells and in breast cancer cells are very different, and they reflect the 
quite different physiological effects of E2 on these target cells.  Further, E2 down-
regulated the expression of few genes in these ER-containing osteosarcoma cells, 
whereas E2 down-regulated the expression of more genes in ER-positive MCF-7 breast 
cancer cells than it up-regulated (29).  Despite these marked differences in genes 
regulated in these two different types of estrogen target cells, some genes were stimulated 
by E2 in both U2OS and MCF-7 breast cancer cells.  These included pS2, keratin 19, the 
sodium hydrogen exchanger regulatory factor (NHERF/EBP50), GREB1, PDZK1, 
RIP140, WISP2 and connexin 43, all previously shown to be under estrogen regulation, 
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as referenced in Tables 2.2 and 2.3.  Some have important roles in cell cytoarchitecture 
and cytoskeletal regulation (e.g., NHERF/EBP50, connexin43), supporting the known 
effects of estrogen on the cytoskeleton of both mammary (63) and bone cells.   
 It is of interest that our time-course analysis in the U2OS cells (Fig. 2.3) revealed 
that genes regulated by E2 divided into 3 temporal patterns, denoted E, E+L,or L in 
Tables 2.2 and 2.3:  those regulated at early times only (4 and/or 8 h), those regulated at 
both early and late times, and those showing increased expression only at late times (24 
and/or 48h). In both MCF-7 and in ER-containing U2OS cells, approximately equal 
numbers of stimulated genes fell into the early and late, and late-only categories, whereas 
relatively few genes showed early-only regulation in the U2OS cells compared with the 
breast cancer cells where ca. one-third of the total stimulated genes showed the early-
only expression pattern.  We have used the protein synthesis inhibitor, cycloheximide, to 
begin to distinguish primary versus secondary effects of E2-ER complexes on regulation 
of some of the interesting genes we have identified in the U2OS cells.  These studies 
reveal that some of the genes turned on early that show elevated expression over time and 
hence fall into the “early and late” category (such as GREB1, autotaxin, oligophrenin-1 
and KLRC4) likely represent primary estrogen response genes since their increase in 
mRNA expression is not prevented by cycloheximide.  In contrast, cycloheximide 
blocked the estrogenic stimulation of cystatin D and PDZK1, a late and an early and late 
gene, respectively, suggesting these are probably secondary response genes.  
Novel estrogen-regulated genes and genes regulated selectively by ERα or ERβ 
 These studies have enabled us to compare the actions of ERα and ERβ.  While 
the majority of E2-stimulated genes were regulated through both ER subtypes, we 
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identified a number of genes selectively regulated either by ERα or by ERβ, as well as 
many novel estrogen-regulated genes (64).  Most of the E2-regulated genes involved in 
cytoskeleton regulation and motility, signal transduction, cytokine and immune response 
and growth factors/hormones were commonly regulated through both receptors.  These 
included a marked up-regulation of cox-2, cyritestin 1, keratin 19, several interleukins 
and integrin α6.  The latter factor, integrin α6, forms laminin receptors when 
heterodimerized with integrin β1 or β4 subunits, and it is one of the factors involved in 
tumor invasion through basal membranes (65-67).  
Important growth factors and hormones regulated by E2 through both receptors 
included several that can act in either an autocrine or paracrine manner, including BMP6 
and PTHLH, to effect the bone-protective actions of E2 (68).  PTHLH, a homologue of 
PTH (parathyroid hormone), acts as an anabolic agent in osteoporosis (62), and its 
overproduction in breast and prostate cancers is associated with bone metastasis of these 
tumors (69, 70).  Hence, its up-regulation by E2 via either ERα or ERβ is of interest. Of 
the genes we observed to be selectively regulated by one ER subtype, nearly three-fourths 
were ERα-selective.  These ERα-regulated genes included several associated with 
nucleic acid processing, two zinc finger proteins, the coregulator TRAP240, and the 
cytochrome P450 family member 2B6 (CYP2B6).  Of the genes exclusively regulated by 
ERβ were autotaxin and cystatin D, factors associated with motility/cytoskeleton and 
cytokine/immune function.   
A recent report of related studies in U2OS cells identified some similar and some 
different gene targets for ERα and ERβ (71) as we observed in this report.  There are 
several important methodological differences between the two studies that could account 
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for some of the differences in findings.  First, the levels of ERα and ERβ in the U2OS 
cells used by Monroe et al (71) were very high, namely three times that of MCF-7 cells, 
whereas we chose to use cells that contained ER at levels more comparable to those in 
osteoblasts, about 20% that of MCF-7 cells.  Also, the studies in ref. 71 examined E2 
regulation only at 24 h, whereas we examined gene regulation over a time course of E2 
treatment up to 48 h, so that we identified both early, early and late, and late-only 
responding genes; hence, some different sets of genes would likely be identified in the 
two studies.  In addition, we used a confidence score that includes considerations of fold 
change, p-values, expression level and present calls in defining estrogen-regulated genes, 
whereas Monroe et al (71) used fold change only.  Further, the studies reported in ref. 71 
used an earlier version Affymetrix microarray chip that contains probes for about half of 
the genes on the U95A array we used, and also uses fewer and different probe sets per 
gene.  Hence, it is not surprising that there are some differences in the observed pattern of 
gene regulations between our study and that presented in ref. 71.   
 The differences in gene targets of ERα vs. ERβ, or of progesterone receptor-A vs. 
progesterone receptor-B (72), may reflect differences in the activation functions of these 
receptors, in particular their N-terminal activation regions, as well as the complexity of 
gene regulation by hormone occupied-nuclear receptors.  The latter involves a 
combination of aspects (7, 16, 73): the diverse nature of target gene promoters (with 
different response elements that may be simple or composite) where receptors may bind 
directly to the DNA or act through tethering to other DNA-bound transcription factors; 
the nature of the coregulators recruited to the hormone-receptor-gene promoter; and the 
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receptor protein conformations induced by different ligands in the context of associated 
coregulators and transcription factors.   
These studies, which have allowed a comparison of the gene regulatory activities 
of ERα and ERβ, should assist in the characterization of genes and cellular signaling 
pathways regulated by E2 through ERα and/or ERβ.  They highlight commonality but 
also significant differences in gene targets for these two ERs and have identified many 
novel genes not previously known to be under estrogen regulation.  Several of these are 
likely to play significant roles in the bone maintenance and anti-osteoporosis effects of 
estrogens. It will be of interest in subsequent studies to use the preferentially regulated 
genes we have identified to explore the molecular basis for the ER subtype-selectivity in 
the regulation of these genes. 
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The abbreviations used are: AP-1, activation protein-1; BMP6, bone 
morphogenetic protein 6; BSA, bovine serum albumin; CAT, chloramphenicol 
acetyltransferase; CS, confidence score; CYP2B6, cytochrome P450 family 2B6; DPN, 
diarylpropionitrile; E2, 17β-estradiol; ERE, estrogen response element; ERα, estrogen 
receptor alpha; ERβ, estrogen receptor beta; FAK, focal adhesion kinase; FBS, fetal 
bovine serum; GFR, guanine nucleotide exchange factor for Rap1; IL-24, interleukin 24; 
IL-8, interleukin 8; LPA, lysophosphatidic acid; NHERF, Na+/H+ exchanger regulatory 
factor; NKG, natural killer cell lectin-type receptors; PCR, polymerase chain reaction; 
PDZK1, PDZ domain containing 1; PPT, propylpyrazoletriol; PR, progesterone receptor; 
PTHLH, parathyroid hormone-like hormone, also known as PTHrP, parathyroid 
hormone-related peptide; RIP140, receptor interacting protein 140; TFF1, trefoil factor 1, 
also known as pS2; TNFα, tumor necrosis factor alpha; TRAP240, thyroid hormone 
receptor-associated protein, 240 kDa subunit; WISP2, WNT1 inducible signaling 
pathway protein 2.  
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Tables and Figures 
 
Table 2.1. Primers used for real-time PCR 
Gene Abbrev. Forward Primer Reverse Primer 
Acyl-CoA Oxidase 2 ACOX2 5'-TTACAGACCCTGACGCAATCC 5'-CCTTAGCAGCCTGGAGGTTGT
Adenosine Kinase ADK 5'-GGGCTGCACCTTTCCTGAGAA 5'-AGCAATTAGGGCAGTGTCTGC
Angiotensinogen AGT 5'-GCCCTTCACTGAGAGCGC 5'- TGAGACCCTCCACCTTGTCC
Autotaxin ENPP2 5'-CTCCTTCATCCTGCCTCACC 5'-TCACGCACCCTAGCTGTGTG 
Bone Morphogenetic 
Protein 6 BMP6 5'-CATCACGGCCACTAGCAATCT 5'-CATCCCTTGTCACCACGCT 
Carbonic Anhydrase XII CA12 5'-GCAGGTCCAGAAGTTCGATGA 5'-CAGACTCAGTCCTGCCGCA 
Connexin 43 GJA1 5'-GCCAAAGACTGTGGGTCTCAA 5'-CCAGGAGGAGACATAGGCGAG
Cystatin D CST5 5'-GACTTTGCCATCAGCGAGTACA 5'-TAGGCAGCCATCACCTGCA 
Estrogen Receptor α ERα/ESR1 5'-GAATCTGCCAAGGAGACTCGC 5'-ACTGGTTGGTGGCTGGACAC 
Estrogen Receptor β ERβ/ESR2 5'-TGTCTGCAGCGATTACGCA 5'-GCGCCGGTTTTTATCGATT 
GREB1 GREB1 5'-CAGGCTTTTGCACCGAATCT 5'-CAAAGCGTGTCGTCTTCAGCT
Integrin Alpha 6 ITGA6 5'-AGATCCCGGCCTGTGATTAA 5'-CCCCACACGCTGTTTTCTG 
Interleukin 24 / MDA-7 IL24 5'-ACTGGACACTTCACGCCCTT 5'-TCACTGGCGCTGCTTAAAGA 
Interleukin 8 IL8 5'-CCAGGAGAAACCACCGGA 5'-GGAAGGCTGCCAAGAGAGC 
Neurotensin NTS 5'-CCAGCTGAGGAAACAGGAGAA 5'-TGAAAAGCCCTGCTGTGACA 
NKG2F KLRC4 5'-AGCACGTCATTGTGGCCATT 5'-GAAGCACAGGCCAGCAAAC 
NOR1/CSMF/MINOR NR4A3 5'-ACCCCGACTACACCAAGCTG 5'-TTGCTCGAGTAGCCCTCCAC 
Oligophrenin 1 OPHN1 5'-GTGGGCTTCAAGTTTGTCAGG 5'-GTGCGGTACAACCCTTCTGTC
PDZK1 PDZK1 5'-CCACTTGACACCCCTCCAGAT 5'-TGTACTGTGGGCCCGTTCTT 
Phospholipase A2, IVA PLA2G4A 5'-TGGCCTTGGTGAGTGATTCAG 5'-TCAAGCCCAGCATGAAGTTG 
Trefoil Factor 1 / pS2 TFF1 5'-ATACCATCGACGTCCCTCCA 5'-AAGCGTGTCTGAGGTGTCCG 
RIP140 NRIP1 5'-AAGCGAAGCCCATTTGCA 5'-TTTGGGAGCTGGTAACTGCC 
SKI-like SKIL 5'-GGAAACTGGCAGTGCCTTTG 5'-CGGAGCATCAGGCTGAACATA
WISP2 WISP2 5'-GCACACCGAAGACCCACCT 5'-AGGTACATGGTGTCGGGCA 
36B4 36B4 5'-GTGTTCGACAATGGCAGCAT 5'-GACACCCTCCAGGAAGCGA 
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Table 2.2.  Genes up-regulated by estradiol through estrogen receptor alpha and 
estrogen receptor beta in U2OS cells.  Genes are organized alphabetically.  The Table 
lists genes determined to be E2-regulated based on a Confidence Score ≥11 and a fold 
change ≥2.0 from microarray analysis, as described in Materials and Methods, in ERα- or 
ERβ-containing cells with the other receptor giving gene stimulation ≥1.4 fold.  Gene 
names in bold appear to be novel and not previously reported to be regulated by E2(†).  
Those in italics have been verified by real-time PCR and the real-time PCR values are 
shown as entries in parentheses under the microarray values.  All values are mean ± SEM.  
Under Time Pattern, E, E+L, or L denote an early only, early and late, or late only time 
pattern of regulation by E2.  
Name Abbrev. GenBank Fold ERα (mean±SEM) 
Fold ERβ 
(mean±SEM) 
Time 
Pattern 
(ERα,ERβ) 
Function 
E2- 
Reg. 
Gene 
Acyl-CoA Oxidase 2 ACOX2 X95190 6.72 ± 2.73 (3.61 ± 0.03)
2.00 ± 0.22 
(2.32 ± 0.33) 
E+L, L housekeeping † 
Adenosine Kinase ADK U50196 2.75 ± 0.59 (2.47 ± 0.33)
1.68 ± 0.31 
(2.07 ± 0.34) 
E+L, L signal 
transduction † 
Angiotensinogen AGT K02215 2.00 ± 0.49 (4.41 ± 0.32)
2.13 ± 0.19 
(4.18 ± 0.50) 
L, L growth factors/ 
hormones (74) 
Baculoviral IAP-
containing 3 BIRC3 U45878 2.47 ± 0.32 3.01 ± 1.17 
L, E+L apoptosis/ 
proliferation † 
Bone Morphogenetic 
Protein 6 BMP6 M60315 
2.39 ± 0.41 
(2.84 ± 0.15)
2.17 ± 0.27 
(2.82 ± 0.09) 
L, L growth factors/ 
hormones (75) 
Cadherin 19, Type 2 CDH19 AF047826 6.49 ± 1.30 1.86 ± 0.48 E+L, E cell motility/ cytoskeleton † 
Carbonic Anhydrase XII CA12 AF037335 2.60 ± 0.24 (5.08 ± 1.04)
2.40 ± 0.04 
(15.42 ± 4.22)
E+L, E+L unknown/other † 
CD34 Antigen CD34 S53911 1.94 ± 0.25 3.12 ± 1.05 L, E+L cytokine/immune function † 
Clone IMAGE 446411  AJ011980 4.67 ± 1.34 6.98 ± 2.73 L, L unknown/other † 
Coagulation Factor XIII, 
A1  F13A1 M14539 4.37 ± 1.08 5.54 ± 0.96 
E+L, E+L unknown/other † 
Connexin 43 GJA1 X52947 2.39 ± 0.30 (2.72 ± 0.13)
1.56 ± 0.06 
(2.21 ± 0.36) 
L, L cell motility/ 
cytoskeleton (60) 
Cyclooxygenase-2 PTGS2 U04636 31.5 ± 1.88 6.64 ± 2.01 E+L, E+L cytokine/immune function (40) 
Cyritestin 1 ADAM3A X89656 4.73 ± 0.20 4.64 ± 2.33 E+L, E cell motility/ cytoskeleton † 
Defensin Beta 1 DEFB1 AI309115 2.01 ± 0.21 1.54 ± 0.40 L, L cytokine/immune function † 
Glycerol Kinase GK X78711 3.57 ± 1.28 4.72 ± 0.14 L, E+L housekeeping (40) 
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Table 2.2. (Cont.) 
G-protein Coupled 
Receptor Kinase 5 GPRK5 L15388 2.13 ± 0.03 2.00 ± 0.26 
E, E signal 
transduction † 
GREB1 Protein GREB1 AB011147 2.74 ± 0.27 (25 ± 3.65) 
4.86 ± 1.88 
(35.76 ± 4.22)
E+L, E+L unknown/other (76) 
Hevin SPARCL1 X86693 4.31 ± 2.37 3.22 ± 2.31 E+L, E+L unknown/other † 
Homeobox HB9 HLXB9 U07664 2.23 ± 0.22 1.63 ± 0.27 E, E nucleic acid processing † 
IL13 Receptor Alpha 2 IL13RA2 U70981 2.64 ± 0.39 1.80 ± 0.14 E+L, L cytokine/immune function † 
Integrin Alpha 6 ITGA6 S66213 3.77 ± 0.89 (3.68 ± 0.36)
2.92 ± 0.12 
(2.28 ± 0.43) 
E+L, L cell motility/ 
cytoskeleton (77) 
Interleukin 8 IL8 M28130 2.13 ± 0.21 (2.79 ± 0.52)
2.40 ± 0.02 
 (3.2 ± 0.40) 
L, E cytokine/immun
e function (78) 
Interleukin 24 / MDA-7 IL24 U16261 5.20 ± 1.25 (10.12 ± 1.56)
1.70 ± 0.34 
(3.76 ± 0.92) 
E+L, E apoptosis/ 
proliferation † 
Keratin 19 KRT19 Y00503 8.99 ± 0.52 3.79 ± 1.32 E+L, L cell motility/ cytoskeleton (59) 
Leucine-rich and Ig 
Domain 1 LRIG1 AL039458 2.50 ± 0.16 1.47 ± 0.10 
E+L, E signal 
transduction † 
Microseminoprotein Beta MSMB AA532495 14.0 ± 1.68 2.83 ± 0.74 E+L, L growth factors/ hormones (79) 
Neurotensin NTS U91618 4.95 ± 1.44 (4.55 ± 0.15)
1.97 ± 0.97 
(3.07 ± 0.08) 
E+L, L growth factors/ 
hormones (80) 
NHERF SLC9A3R1 AF015926 1.97 ± 0.08 2.22 ± 0.10 L, E+L signal transduction (27) 
NKG2C KLRC2 AJ001684 8.13 ± 1.50 6.74 ± 1.08 E+L, E+L cytokine/immune function † 
NKG2E KLRC3 AJ001685 8.91 ± 0.54 7.14 ± 1.66 E+L, E+L cytokine/immune function † 
NKG2F KLRC4 AJ001683 2.94 ± 1.64 (9.75 ± 1.62)
2.67 ± 0.01 
(14.42 ± 2.67)
E+L, E+L cytokine/immun
e function † 
NOR1/CSMF/MINOR NR4A3 X89894 1.38 ± 0.57 (2.74 ± 0.11)
2.00 ± 0.22 
(4.17 ± 0.65) 
L, E nucleic acid 
processing † 
Oligophrenin 1 OPHN1 AJ001189 2.09 ± 0.37 (2.48 ± 0.44)
1.99 ± 0.23 
(3.9 ± 1.03) 
E+L, E+L cell motility/ 
cytoskeleton † 
Parathyroid Hormone-like 
Hormone 
PTHLH/  
PTHrP M24351 2.29 ± 0.01 2.80 ± 0.35 
E+L, E+L growth factors/ 
hormones (81) 
PDZK1 Protein PDZK1 AF012281 2.33 ± 0.77 (7.96 ± 1.35)
5.76 ± 0.47 
(8.23 ± 1.31) 
E+L, E+L signal 
transduction (76) 
Phosphodiesterase 4B PDE4B L20971 2.10 ± 0.05 1.40 ± 0.06 E, E+L signal transduction † 
Phospholipase A2, IVA PLA2G4A M72393 2.91 ± 1.38 (2.04 ± 0.12)
2.79 ± 1.90 
(4.31 ± 0.45) 
E+L, L cytokine/immun
e function † 
Protein Phosphatase 1, 
Subunit 12B PPP1R12B AB007972 2.97 ± 0.05 2.32 ± 0.11 
E+L, E+L signal 
transduction (29) 
pS2 TFF1 AA314825 3.38 ± 0.21 (20.35 ± 3.62)
3.17 ± 0.96 
(8.27 ± 1.55) 
L, L cytokine/immun
e function (82) 
Putative Tumor 
Suppressor FUS2 U73167 2.28 ± 0.15 2.17 ± 0.17 
L, L signal 
transduction † 
Ras Protein Specific GRF 
1 RASGRF1 S62035 2.03 ± 0.04 1.94 ± 0.01 
L, L signal 
transduction (29) 
Ras-like Protein A RALA M29893 2.04 ± 0.06 1.45 ± 0.28 L, L signal transduction † 
Ret/Ptc2 Fusion  HG4677-HT5102 2.27 ± 0.13 2.03 ± 0.37 
L, L unknown/other (29) 
Rho-related BTB 
Domain Containing 3 RHOBTB3 AB020685 2.06 ± 0.03 1.62 ± 0.36 
E+L, L signal 
transduction † 
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Table 2.2. (Cont.) 
RIP140 NRIP1 X84373 2.88 ± 0.12 (3.35 ± 0.45)
1.54 ± 0.10 
(2.45 ± 0.18) 
E+L, L nucleic acid 
processing (83) 
Selenoprotein P1 SEPP1 Z11793 2.14 ± 0.17 2.18 ± 0.33 L, L cytokine/immune function † 
SKI-like SKIL X15217 2.51 ± 0.22 (1.91 ± 0.20)
1.49 ± 0.51 
(2.4 ± 0.31) 
E+L, E nucleic acid 
processing † 
Transcobalamin 1 TCN1 J05068 5.83 ± 0.59 11.6 ± 1.25 L, L housekeeping † 
Transcortin SERPINA6 J02943 6.24 ± 0.25 2.63 ± 0.97 E+L, L growth factors/ hormones (84) 
Transducin-like, 
Enhancer of Split 3 TLE3 M99438 2.36 ± 0.29 2.28 ± 0.01 
E, E unknown/other † 
UDP-
glycosyltransferase 2, 
B10 
UGT2B10 X63359 6.80 ± 2.32 2.25 ± 0.77 
E+L, E+L 
housekeeping † 
WISP2 WISP2 AF100780 3.89 ± 0.25 (42.2 ± 7.59)
2.81 ± 0.26 
(14.19 ± 1.38)
L, L cell motility/ 
cytoskeleton (58) 
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Table 2.3. Estrogen-stimulated genes regulated selectively through one estrogen 
receptor subtype.  E2-up-regulated genes were classified as ER-subtype selective when 
the Confidence Score was ≥11 and the fold change as determined by microarray analysis 
was 2.0 or greater whereas fold change was less than 1.3 fold for the other receptor at all 
time points. Gene names in bold appear to be novel and not previously reported to be 
regulated by E2(†).  Those in italics have been verified by real-time PCR and the real-
time PCR values are shown as entries in parentheses under the microarray values.  All 
values are mean ± SEM.  Under Time Pattern, E, E+L, or L denote an early only, early 
and late, or late only time pattern of regulation by E2. 
Name Abbrev. GenBank Fold (mean±SEM) 
Time 
Pattern Function  
E2- 
Reg. Gene 
ERα-selective       
 
    
Cytochrome P450, Family 2 B6 CYP2B6 M29874 6.10 ± 0.15 E+L housekeeping † 
Phosphodiesterase 3B PDE3B D50640 3.50 ± 0.83 E+L signal transduction † 
RIESKE Iron-Sulfur Protein   M23316 3.20 ± 0.72 E+L unknown/other † 
Chromosome 18, orf 1 C18ORF1 AF009426 2.65 ± 0.65 E+L unknown/other † 
Sodium Channel, Non-voltage 
Gated 1, β SCNN1B X87159 2.57 ± 0.27 
E+L signal 
transduction † 
Sialomucin CD164 D14043 2.50 ± 0.05 
L cytokine/immune 
function † 
Zinc Finger Protein 267 ZNF267 X78925 2.41 ± 0.17 
L nucleic acid 
processing † 
PCF11p Homolog PCF11 AB020631 2.42 ± 0.27 
L nucleic acid 
processing † 
Zinc Finger Protein 148 ZNF148 L04282 2.39 ± 0.28 
L nucleic acid 
processing † 
TR-associated Protein, 240 kDa TRAP240 AB011165 2.21 ± 0.23 
L nucleic acid 
processing † 
CD2-associated Protein CD2AP AL050105 2.17 ± 0.12 
L cell motility/ 
cytoskeleton † 
DKFZp586K1 Protein DKFZp586K1 AL049382 2.16 ± 0.21 L unknown/other † 
KIAA0626 Gene Product KIAA0626 AB014526 2.16 ± 0.35 L unknown/other † 
Bcl-2-associated Transcription 
Factor BTF D79986 2.13 ± 0.05 
L apoptosis/ 
proliferation † 
DKFZp434D193   U79263 2.13 ± 0.35 E+L unknown/other † 
Hbc647 mRNA hbc647 U68494 2.12 ± 0.06 L unknown/other † 
PKC Binding Protein 1 PRKCBP1 U48251 2.12 ± 0.37 
L signal 
transduction (85) 
ATPase, Lysosomal, V1 
Subunit D ATP6V1D AA877795 2.09 ± 0.13 
L 
unknown/other † 
KIAA0191 Protein KIAA0191 D83776 2.09 ± 0.03 E+L unknown/other † 
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Kinesin Family Member 5B KIF5B X65873 2.07 ± 0.58 
L cell motility/ 
cytoskeleton † 
PRP4 pre-mRNA Processing 
Factor 4B PRPF4B U48736 2.07 ± 0.01 
E+L nucleic acid 
processing † 
KIAA0372 Gene Product KIAA0372 AB002370 2.01 ± 0.15 L unknown/other † 
KIAA1033 Protein KIAA1033 AB028956 2.01 ± 0.22 L unknown/other † 
Clone wg82b12.x1   AI768188 2.00 ± 0.17 L unknown/other † 
ERβ-selective            
Clone 23892   AF035317 7.24 ± 1.24 E+L unknown/other † 
Autotaxin ENPP2 L35594 
5.73 ± 1.77 
(8.98 ± 0.78)
E+L cell motility/ 
cytoskeleton † 
Cystatin D CST5 X70377 
3.70 ± 1.27 
(8.17 ± 1.02)
L cytokine/immune 
function † 
HSU43279   U43279 3.53 ± 0.79 E+L unknown/other † 
RA-inducible Endogenous 
Retroviral DNA   M64936 3.37 ± 0.59 
E+L 
unknown/other † 
Rap1 GEF GFR D87467 2.41 ± 0.17 
E signal 
transduction † 
Stromal Antigen 2 STAG2 Z75331 2.28 ± 0.51 E+L unknown/other † 
Putative Mitochondrial Space 
Protein PSORT AF050198 2.2 ± 0.09 
E 
unknown/other † 
Hypothetical Protein FLJ31564 W27600 2.2 ± 0.38 E+L unknown/other † 
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Figure 2.1.  Characterization of U2OS human osteosarcoma cells stably expressing 
ERα or ERβ.  
(A) Estrogen receptor mRNA copy number/10 ng total RNA as assessed by real-time 
PCR in ERα clones 1-4 and in ERβ clones 1-4.  (B) E2 binding sites/mg protein 
evaluated by E2 binding assay in parental U2OS and U2OS-ER cell lines (ERα clone 1 
48
 
 
Figure 2.1. (Cont.) 
and ERβ clone 1) in comparison with the MCF-7 breast cancer cell line. The mean of 
closely corresponding duplicate determinations is shown.  (C) Western blot for ERα and 
ERβ protein in different clones of stably transfected U2OS cells.  (D) Motility (Boyden 
chamber assay) of cells (ERα clone 1 and ERβ clone 1) was assayed with 5% FBS as a 
general chemoattractive factor. E2 treatment was for 48 h. Similar findings were obtained 
with 3 other ERα and ERβ clones. E) Adhesion assay was performed in 96-well plates 
coated with various substrates. Shown is 30 min adhesion on collagen type I measured as 
absorbance at 570 nm. E2 treatment was for 48 h. No effect of E2 on cell adhesion was 
also seen in repeat experiments with 3 other ERα and ERβ clones. *p<0.01 for E2-treated 
cells vs. cells treated with control vehicle. 
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Figure 2.2.  Cluster analysis of E2-regulated genes in U2OS-ERα or -ERβ 
containing cells.  
After applying normalization and confidence score analyses, all the E2-regulated genes in 
U2OS-ER containing cells (ERα clone 1 and ERβ clone 1) were clustered using a 
standard correlation algorithm (GeneSpring software). Up-regulated genes are shown in 
red, down-regulated genes in blue and non-changing genes in yellow. The color scale 
corresponding to fold change in gene expression is shown at the left. The different time 
points of the E2 (10nM) time-course treatment are indicated at the right. The gene 
expression values shown are the average fold change of independent samples, each run 
on a separate microarray chip, for each time point.  
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Figure 2.3.  Time-course patterns of E2-stimulated genes in U2OS-ERα and U2OS-
ERβ cells as identified from microarray analysis. 
All E2 up-regulated genes were assigned to one of three categories. For “Early only” 
regulated genes (dotted broken line with diamonds), the fold change was 2-fold or greater 
at 4 and/or 8 h only. For “Early and Late” regulated genes (dashed line with triangles), 
the fold change was 2-fold or greater at 4 and/or 8 h and at 24 and/or 48 h. And for “Late 
only” regulated genes (solid line with squares), the fold change was 2-fold or greater at 
24 and/or 48 h only. Once genes were assigned to one of the three time-course patterns, 
the mean fold-change ± SEM was calculated and plotted for all genes in that pattern. On 
some points, error bars are too small to be visible.  
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Figure 2.4.  Functional classification of E2-stimulated genes. 
E2 up-regulated genes were classified as ER-subtype selective when the fold change from 
the microarray data for one receptor was 2.0-fold or greater whereas for the other 
receptor it was less than 1.3-fold at all time points. All the genes identified were then 
categorized in functional groups according to their main known function based on 
LocusLink, OMIM, PubMed, GeneCards and GenMAPP databases.  
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Figure 2.5.  Real-Time PCR validation of genes regulated commonly by both ERα 
and ERβ.  
Estradiol (10nM) time-course and ICI 182,870 (1µM) treatments were performed in three 
independent experiments to confirm DNA microarray data and assess the estrogen 
receptor-dependent mechanism of the gene regulation through reversal by a 100-fold 
excess of the antiestrogen (ICI+E2). Values are mean fold change + SEM. *indicates 
p<0.05 for gene stimulation by E2 vs. vehicle control.  
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Figure 2.6.  Real-Time PCR validation of genes regulated selectively through ERβ. 
Estradiol (10nM) time-course and ICI 182,870 (1µM) treatments were performed in three 
independent experiments to confirm DNA microarray data and assess the estrogen 
receptor-dependent mechanism of the gene regulation through reversal by a 100-fold 
excess of the antiestrogen (ICI+E2). Values are mean fold change + SEM. *indicates 
p<0.05 and † indicates p=0.06 for gene stimulation in ERβ- vs. ERα-containing cells.  
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Figure 2.7.  Real-Time PCR analysis of gene regulation by estradiol, the ERα-
selective ligand PPT, the ERβ-selective ligand DPN, and Genistein. 
Estradiol (10nM), PPT (100nM), DPN (100nM), and Genistein (1µM) treatments were 
performed for 48 h in three separate experiments to examine the ability of ER-subtype 
selective ligands to regulate gene expression in cells containing either ERα or ERβ. 
Values are mean fold change + SEM. *indicates p<0.05 and † indicates p=0.07 for gene 
stimulation in ERβ- vs. ERα-containing cells.   
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CHAPTER 3 
ESTROGEN RECEPTOR REGULATION OF CARBONIC ANHYDRASE XII 
THROUGH A DISTAL ENHANCER IN BREAST CANCER1 
 
Abstract 
The expression of carbonic anhydrase XII (CA12), a gene that encodes a zinc-
metalloenzyme responsible for acidification of the microenvironment of cancer cells, is 
highly correlated with estrogen receptor α (ERα) in human breast tumors. Here, we show 
that CA12 is robustly regulated by estrogen via ERα in breast cancer cells, and that this 
regulation involves a distal estrogen-responsive enhancer region.  Upon addition of 
estradiol, ERα binds directly to this distal enhancer in vivo, resulting in the recruitment of 
RNA polymerase II and steroid receptor coactivators SRC-2 and SRC-3, and changes in 
histone acetylation.  Mutagenesis of an imperfect estrogen-responsive element within this 
enhancer region abolishes estrogen-dependent activity, and chromosome conformation 
capture (3C) and chromatin immunoprecipitation assays demonstrate that this distal 
enhancer communicates with the transcriptional start site of the CA12 gene via intra-
chromosomal looping upon hormone treatment. This distal enhancer element is observed 
in the homologous mouse genomic sequence, and the expression of the mouse homolog, 
Car12, is rapidly and robustly stimulated by estradiol in the mouse uterus in vivo, 
suggesting that the ER regulation of CA12 is mechanistically and evolutionarily 
conserved. Our findings highlight the crucial role of ER in regulation of the CA12 gene, 
                                                 
1 This work was originally published in Cancer Research 68(9):3505-3515, doi:10.1158/0008-5472.CAN-
07-6151 
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and provide insight into the transcriptional regulatory mechanism that accounts for the 
strong association of CA12 and ER in human breast cancers.  
 
Introduction 
 Estrogen receptor alpha (ERα), a hormone-regulated transcription factor and 
member of the superfamily of nuclear receptors (1, 2), is expressed in approximately 70 
percent of breast cancers (3).  As the major regulator of the phenotypic properties of these 
breast cancers, ERα markedly influences the pattern of breast cancer gene expression and, 
perhaps more than any other protein, it defines the distinctly different gene signatures of 
ER-positive and ER-negative breast cancers (4-7).   In our recent breast cancer gene 
expression profiling studies, we observed the carbonic anhydrase XII gene (CA12) to be 
robustly stimulated by estradiol (E2) in several ER-containing breast cancer cells (8, 9). 
Further, from our examination of transcriptional profiling data sets in ER-positive and 
ER-negative breast tumors, we found CA12 to show one of the most highly significant 
positive correlations with ER expression (10-12).  
Carbonic anhydrase XII is a transmembrane, extracellular enzyme and member of 
the family of zinc-metalloenzymes that catalyze the reversible hydration of CO2 to form 
bicarbonate (H2O + CO2 ÅÆ H+ +HCO3-), thereby regulating the microenvironment 
acidity and tumor malignant phenotype (13-16).  CA12 was originally identified as a 
protein overexpressed in renal cancer cells (13), but is now known to be also 
overexpressed in some other cancers, including breast cancer (17, 18).  While both CA12 
and the closely related tumor-associated carbonic anhydrase IX (CA9) are thought to be 
regulated by hypoxia, only CA12, and not CA9, exhibits a strong positive correlation 
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with ER expression in breast tumors (4, 19) suggesting that CA12 might be under ER 
regulation. CA12 expression in breast tumors is associated with positive ERα status, 
lower grade disease, lower relapse rates, and better overall patient survival (20-22). 
To understand the mechanistic basis underlying this strong association between 
ER positivity and CA12 expression, we have in the work reported here, explored the 
regulation of CA12 by the ER. Our results document that the CA12 gene is under primary 
transcriptional up-regulation by the estrogen-occupied ER and that this regulation in 
breast cancer cells is mediated by ER action through a distal enhancer that we newly 
characterize. Upon estrogen stimulation, this enhancer binds ERα through an imperfect 
estrogen response element and recruits p160 coactivators.  Furthermore, by chromosomal 
looping this ER-dependent enhancer communicates with the promoter of the CA12 gene, 
markedly enhancing transcription of the CA12 gene.  Our findings define a mechanistic 
basis for the robust coexpression of CA12 and ER in breast cancer.    
 
 
Materials and Methods 
Cell Culture and Experimental Treatments 
 MCF-7 cells were maintained in Minimal Essential Medium (MEM) (Sigma 
Chemical Co., St Louis, MO) supplemented with 5% calf serum (HyClone, Logan, UT), 
100 µg/ml penicillin/streptomycin (Invitrogen, Carlsbad, CA), and 25 µg/ml gentamicin 
(Invitrogen).  T47D cells were routinely maintained in MEM and antibiotics 
supplemented with 5% fetal bovine serum (Atlanta Biologicals, Atlanta, GA) and bovine 
insulin (6 ng/ml; Sigma, St. Louis, MO).  All cells were grown in phenol red-free MEM 
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supplemented with 5% charcoal-dextran-treated serum for at least five days prior to use 
in experiments.  
Animal Care and Treatments 
 Eight week old ovariectomized C57BL/6 mice were obtained from Harlan Co. 
(Indianapolis, IN) and housed under controlled conditions of light and temperature with 
free access to standard chow and water. All experiments were conducted in accordance 
with the principles and procedures of the NIH Guide for the Care and Use of Laboratory 
Animals and were approved by the University of Illinois Institutional Animal Care and 
Use Committee. At 16 days after ovariectomy, mice were injected sc with E2 (0.5 
µg/animal) dissolved in DMSO then diluted 1:10 in corn oil or with control vehicle 
DMSO:corn oil alone.  At 4 or 24 h after hormone or vehicle injection, uteri were 
removed, weighed after removal of associated fat, and snap-frozen in liquid nitrogen for 
RNA isolation. 
RNA Isolation, Reverse Transcription, and Real-Time PCR 
Cell and whole uterine total RNA was prepared using TRIzol reagent (Invitrogen) 
according to the manufacturer’s recommendations.  RNA samples were reverse 
transcribed in a total volume of 20 µl using 200 units of reverse transcriptase, 50 pmol 
random hexamer, and 1 mM deoxynucleotide triphosphates (New England Biolabs, 
Beverly, MA). The resulting cDNA was then diluted to a volume of 500 µl nuclease-free 
water.  Real-time PCR was performed on an ABI Prism 7900HT instrument using SYBR 
Green PCR Master Mix (Applied Biosystems, Foster City, CA) according to the 
manufacturer’s recommendations. Briefly, each PCR contained: 1x master mix, 4 µl of 
the diluted cDNA reaction, and 50 nM forward and reverse primers designed to yield 80- 
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to 125-bp amplicons. PCR was carried out through 40 cycles (95°C for 15 sec, 60°C for 1 
min) following an initial 10 min incubation at 95°C. Relative expression levels were 
calculated as described previously, using acidic ribosomal protein 36B4 mRNA as an 
internal control (9).  Real-time PCR of ChIP samples was performed in a similar manner, 
with appropriate primers. 
Small Interfering RNA Studies 
siRNA duplexes targeting ERα (forward, UCAUCGCAUUCCUUGCAAAdTdT; 
reverse,  UUUGCAAGGAAUGCGAUGAdTdT, and control (GL3 luciferase, #D-
001400-01) were obtained from Dharmacon (Lafayette, CO) and transfected into cells at 
a final concentration of 20 nM using DharmaFECT transfection reagent as per the 
manufacturer’s recommendations at 72 h prior to ligand treatment.  
Immunoblotting 
Whole cell lysates of MCF-7 cells were prepared using 1x Cell Lysis Buffer (Cell 
Signaling Technology, Beverly, MA) in the presence of Complete Mini protease inhibitor 
cocktail (Roche Applied Science, Indianapolis, IN). Protein concentration of whole cell 
lysates was determined by BCA Protein Assay (Pierce, Rockford, IL). Proteins (20 μg) 
were boiled in 2x Laemlli buffer and separated by electrophoresis using 10% 
polyacrylamide gels containing sodium dodecyl sulfate (SDS-PAGE) at 150 volts for 50 
min and were then transferred to a nitrocellulose membrane (Pall Corp., Pensacola, FL), 
using the wet transfer method, at 100 volts for 90 min. Membranes were blocked with 5% 
milk in TBS. Rabbit-anti-human CA12 primary antibody (13) was incubated with 
blocked membrane overnight at 4°C. The blot was then washed with TBS containing 
0.1% Tween-20 prior to incubation with HRP-conjugated secondary antibody (Zymed 
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Antibodies, South San Francisco, CA). The blot was incubated with Super Signal West 
Femto ECL reagents (Pierce, Rockford, IL) and exposed to film in order to observe 
protein bands.  
Genomic Cloning, Mutagenesis, and Luciferase Reporter Assays 
The indicated genomic DNA associated with estrogen receptor binding and 
intervening regions was amplified by PCR from human genomic DNA (Roche Molecular 
Biochemicals, Indianapolis, IN) using specific primers and cloned into either pGL3-
Promoter or pGL3-Basic luciferase vectors (Promega, Madison, WI) using the MluI and 
BglII sites.  Site-directed mutagenesis was performed using QuikChange II kit 
(Stratagene, LaJolla, CA) as per manufacturer’s directions.  All constructs were 
sequenced to verify their correctness.  Briefly, 1000 ng pGL3 reporter vector and 25 ng 
pRL-SV40 were co-transfected into MCF-7 cells in 24-well plates using Lipofectamine 
2000 in OptiMEM as per manufacturer’s instructions (Invitrogen, Carlsbad, CA).   Cells 
were transfected for 6 h, washed, and treated with indicated ligands for 16 h prior to cell 
lysis in 1x passive lysis buffer (Promega, Madison, WI) and measurement of luciferase 
activity in MLX Microtiter Plate Luminometer (Dynex Technologies, Chantilly, VA).   
Chromatin Immunoprecipitation (ChIP) Assays 
 Whole-genome ERα binding sites were mapped in MCF-7 cells treated with 10 
nM E2 for 45 min using a chromatin immunopreciptation-Paired End diTag (ChIP-PET) 
cloning and sequencing strategy described previously (23), from which data was obtained 
on ERα binding sites near the CA12 gene. Standard ChIP assays were performed 
essentially as previously described (24, 25) with a few noted modifications.  Following 
the addition of ethanol vehicle or ligands for indicated times, MCF-7 cells were 
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crosslinked using 1% formaldehyde at 37°C for 10 min, washed twice with PBS, and 
harvested in ice-cold PBS plus 1x protease inhibitor cocktail (Roche) and 10 mM DTT. 
Cell pellets were first resuspended in nuclei isolation buffer (50 mM Tris-HCl, pH 8.0. 60 
mM KCl, 0.5% NP40, protease inhibitor and 10 mM DTT), centrifuged at 1000 g for 3 
min, and resuspended in lysis buffer (0.5% SDS, 10 mM EDTA, 0.5 mM EGTA, 50 mM 
Tris-HCl, pH 8.0, protease inhibitor and 10 mM DTT).  Nuclei were sonicated (Fisher 
Scientific, Sonic Dismembrator Model 100) at 80% maximum power three times for 10 
seconds and the sonicate was centrifuged at 14,000 g. The supernatant was 1:4 diluted by 
dilution buffer (1% Triton X-100, 2mM EDTA, 150mM NaCl, 20 mM Tris-HCl, pH 8, 
protease inhibitor and 10 mM DTT ) and precleared with 15 μl preimmune IgG (Santa 
Cruz Inc.), 2 μg salmon sperm DNA, 50 µl 25% protein A-agarose slurry (Santa Cruz 
Inc.). Complexes were incubated at 4°C overnight with 2-5 μg antibody, then pulled 
down at 4°C for 1 h with 60 µl of 25% protein A-agarose slurry and 2 μg salmon sperm 
DNA.   Antibodies used were: for ERα (HC-20, Santa Cruz Biotech), RNA Polymerase 
II (N-20, Santa Cruz Biotech), SRC-2 (M-343, Santa Cruz Biotech), SRC-3 (H-270,  
Santa Cruz Biotech) and acetylated histone H4 (07-329, Upstate Biotech).  Precipitates 
were sequentially washed with 1 ml washing buffer (0.1% SDS, 1% Triton X-100, 2 mM 
EDTA, 20 mM Tris-HCl (pH 8.0), 150 mM NaCl ), 1 ml washing buffer II (0.1% SDS, 
1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl (pH 8.0), 500 mM NaCl), 1 ml 
washing buffer III (0.25 mM LiCl, 1% NP40, 1% sodium deoxycholate, 1 mM EDTA, 10 
mM Tris-HCl (pH 8.0)) and twice with 1 ml TE (1 mM EDTA, 10 mM Tris-HCl [pH 
8.0]). Chromatin complexes were incubated at room temperature for 20 min with 100-300 
µl elution buffer (1% SDS, 0.1 M NaHCO3). The crosslinking was reversed by 
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incubating at 65°C overnight with 200 mM NaCl and 200 mg/ml proteinase K 
(Invitrogen Corp.). DNA was purified with QIAquick columns (Qiagen) and amplified by 
real-time PCR. 
Chromosome Conformation Capture (3C) Assays 
MCF-7 cells were grown as per protocol for ChIP assay above and treated with 
indicated ligands for 45 min prior to fixation in 2% formaldehyde at 37°C for 10 min. 
The formaldehyde was quenched with addition of 0.125 M glycine and cells were lysed 
in lysis buffer (10 mM Tris-HCl pH 8.0, 10 mM NaCl, 0.2% NP-40, 1X Complete 
Protease Inhibitors (Roche) at 4°C for 90 min.   Nuclei were resuspended in 1X New 
England Biolabs Buffer 2, 0.3 % SDS and incubated at 37°C for 60 min while rotating. 
Triton-X was added to a final concentration of 1.8 % to sequester the SDS and incubated 
at 37°C for 60 min while rotating.  The chromatin was then digested overnight using 
MseI (New England Biolabs) or BtgI (New England Biolabs) at 37°C while rotating.  
SDS was added to a final volume of 1.6% and the samples were heated at 65°C for 20 
min.  Two μg aliquots of the chromatin samples were diluted in ligation buffer containing 
1% Triton-X and incubated at 37°C for 1 h.  The temperature was lowered to 16°C and 
T4 Ligase (New England Biolabs) was added and samples were incubated overnight.  
The ligated DNA was purified using phenol/chloroform extraction and analyzed using 
PCR amplification.  Resulting PCR products were sequenced and mapped back to the 
USCS Genome Browser for verification.   
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 Results 
CA12 Regulation by Estrogen is a Primary Transcriptional Response Mediated by the 
Estrogen Receptor 
In our prior transcriptional profiling microarray analyses of gene expression 
stimulation by E2 in ER-positive breast cancer and osteosarcoma cells (8, 9, 26), we 
observed a very marked up-regulation of CA12 gene expression by E2. To investigate 
CA12 regulation by estrogen in breast cancer in greater detail, and to elucidate the 
mechanism underlying this regulation, we first examined the time course of CA12 
mRNA and protein increases in response to E2 and SERMs in ERα-positive MCF-7 and 
T47D breast cancer cells.  CA12 RNA was significantly stimulated after 2 h of E2 
exposure and continued to rise to maximal stimulation levels by 4 and 8 h in MCF-7 and 
T47D cells, respectively, and remained greatly elevated throughout the 48 h of treatment 
in both cell lines (Fig. 3.1A).  Increases in CA12 protein levels were detected as early as 
2-4 h, and continued to rise throughout the time course of treatment (Fig. 3.1B), 
consistent with the early and sustained stimulation of CA12 RNA by E2.  The SERMs, 
trans-hydroxy-tamoxifen (Tam) and raloxifene (Ral), induced CA12 RNA 3-4 fold, 
approximately 40% that obtained with E2 (Fig. 3.1C), and in like manner, Tam and Ral 
stimulated CA12 protein to approximately one-third that of E2 (Fig. 3.1D).  The ER full 
antagonist and Selective Estrogen Receptor Down-regulator (SERD), fulvestrant (ICI 
182,780), had no stimulatory effect on CA12 RNA, and it was able to inhibit the E2-, 
Tam-, and Ral-mediated stimulation of CA12 (Fig. 3.1C). Of the other steroid receptor 
ligands examined, only dihydrotestosterone was able to mildly stimulate CA12, possibly 
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through androgen receptor or because of its low affinity for ER (27), whereas the 
glucocorticoid receptor and progesterone receptor agonists, hydrocortisone and 
medroxyprogesterone acetate, respectively, did not regulate CA12 expression (Fig. 3.1C). 
We next examined the requirement of the estrogen receptor itself for E2-mediated 
stimulation of CA12 mRNA.  MCF-7 cells were pre-treated for 60 min with vehicle or a 
two log molar excess of fulvestrant prior to treatment with E2, and CA12 mRNA, and 
protein levels were assessed after 2 or 8 h, respectively (Fig. 3.2A and 3.2B).  Fulvestrant 
did not increase CA12 mRNA or protein, but it was able to fully inhibit the E2-mediated 
up-regulation.  We also examined the requirement of ER in CA12 mRNA stimulation by 
siRNA-mediated depletion of ERα from MCF-7 cells.  MCF-7 cells were transfected 
with siRNA demonstrated to deplete cells of >95% of ERα (data not shown).  Loss of ER 
at 72 h post-transfection reduced the basal CA12 mRNA level, likely due to possible 
ligand-independent ER transactivation activity, and abolished the E2- and SERM-
mediated stimulation of CA12 (Fig. 3.2C).  These results indicate that ER is required for 
and SERM regulation of the CA12 gene. 
In addition to the ER itself, we also determined the requirement of on-going 
transcription and translation for E2 stimulation of CA12.  MCF-7 cells were pre-treated 
for 60 min with the RNA polymerase inhibitor actinomycin D or the translational 
inhibitor cycloheximide for 4 h prior to treatment with E2 (Fig. 3.2A).  The E2-mediated 
stimulation of CA12 mRNA (or Tam- or Ral-mediated increase in CA12 mRNA, not 
shown) was inhibited by actinomycin D, but not cycloheximide, suggesting that on-going 
transcription, but not synthesis of new protein factors, is necessary for CA12 mRNA 
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stimulation by the ER.  Taken together, these results suggest that CA12 regulation by 
estrogen is a primary transcriptional response mediated by the ER. 
 Because of our observations of the requirement for ER for CA12 regulation, we 
examined CA12 expression in primary ER-positive breast tumors by analysis of several 
gene expression data sets from ER-positive breast tumors (Fig. 3.2D). These analyses 
reveal a very positive correlation of CA12 expression with ERα expression in primary 
breast tumors, shown in the scatter plots in Fig. 3.2D. Our findings highlighting the 
crucial role of ER in CA12 up-regulation may account for the robust coexpression of 
CA12 and ERα observed in human breast cancers.  
E2-Bound ER is Recruited to a Distal Region Upstream of the CA12 Transcription Start 
Site In Vivo 
The ER primarily functions as a signal-activated transcriptional transactivator 
through direct binding to DNA response elements or other protein transcription factors 
(24, 28).  To examine the role of ER in regulating CA12 mRNA, we utilized a series of 
chromatin immunoprecipitation (ChIP) experiments to interrogate the recruitment and 
binding of ER to chromatin.  Genome-wide chromatin immunoprecipitation paired-end 
ditag (ChIP-PET) experiments using an antibody against ERα to capture DNA loci bound 
by ER after 45 min of E2 exposure in MCF-7 cells showed a cluster of ER binding DNA 
fragments approximately 6 kilobases upstream from the transcriptional start site of the 
CA12 gene (Fig. 3.3A and 3.3B).   Further examination of this ChIP-PET cluster of 
bound DNA fragments at ~ 6 kb revealed a cluster of five overlapping fragments, and 
two single upstream ChIP-PET DNA fragments considered to be experimental noise (Fig. 
3.3B; (23)).   
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To validate and further examine the extent of ER binding within the CA12 
genomic region, we performed ChIP scanning for ERα in MCF-7 cells treated for 45 min 
with vehicle or 10 nM E2 and amplified recovered ChIP DNA fragments using 100 bp 
primer sets tiled approximately every 500 bp from -6.5 kb to the transcriptional start site 
of the CA12 gene (Fig. 3.3C).  Of note, within this region there are four predicted 
imperfect EREs and multiple response elements for factors to which ERα is known to 
tether (e.g. AP-1), suggesting multiple putative ER binding sites.  ChIP scanning for ERα 
binding revealed robust E2-induced binding at the ~-6 kb binding region previously 
shown to bind ERα through the genome-wide ChIP-PET experiments, and low-level 
binding of ERα at the proximal promoter region, but near-background level binding at 
intervening positions (Fig. 3.3C).  These ChIP assays further define the one robust ERα 
binding region at a distal region approximately 6 kb upstream from CA12.  
E2- and SERM-Induced Transcription Factor Recruitment and Chromatin Modifications 
to CA12 Genomic Regions In Vivo 
To better understand the regulation of the CA12 gene, we further examined the 
recruitment of ER, coactivators, RNAPII, and permissive histone modifications at the 
enhancer, proximal promoter, and additional loci in MCF-7 cells treated with vehicle, 10 
nM E2, or 100 nM trans-hydroxy-tamoxifen.  ChIP experiments coupled with qRT-PCR 
showed specific and robust recruitment of both E2- and Tam-bound ERα at the enhancer 
region after 45 min, with minimal binding to a region upstream of the enhancer or to an 
intermediate position (denoted Middle) at approximately -4 kb (Fig. 3.4).  The binding of 
ER to the enhancer region in E2- or Tam-treated cells remained elevated over vehicle at 4 
and 24 h of exposure.  At the proximal promoter (TSS), the largest subunit of RNA 
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polymerase II was bound to a certain degree in the absence of hormone, but increased 
seven-fold after 45 min of E2, consistent with a well-established role of E2-mediated 
formation of productive transcriptional complexes.  Consistent with the lower potency of 
Tam in stimulation of CA12 gene expression, Tam-treated cells showed less RNAPII 
recruitment at the TSS.  RNAPII was not appreciably recruited to areas upstream of the 
TSS with either E2 or Tam treatments.    
We also examined the recruitment of both of the coregulators SRC-2 and SRC-3 
to the enhancer region in the presence of E2 (Fig. 3.4), and found a large change in 
recruitment of both at 45 min, and also at the 4 h and 24 h times monitored.  In the 
presence of Tam, coactivator recruitment at the enhancer was comparable with that of 
vehicle, suggesting that the Tam-bound ER does not efficiently recruit p160 coregulators, 
as others have observed (29).  To determine the degree of chromatin modifications 
consistent with gene activation, we also examined the level of histone H4 tail acetylation 
(AcH4), considered to be a general marker of acetylated, “relaxed” histones permissive of 
transcriptional regulation.  We observed a marked increase of AcH4 at the enhancer 
region in both E2 and Tam-treated cells (E2 > Tam), which was greatest at 45 min and 
decreased at later times.  This E2- and SERM-mediated increase in AcH4 was noted at 
the TSS and also, interestingly, at the middle and particularly at the upstream regions 
shown not to bind ER.   These are supportive of findings by others showing a high level 
of histone lysine acetylation, consistent with chromatin remodeling, at the active 
enhancer and promoter of stimulated genes (30), as well as more broadly in nearby 
regions. 
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 Estrogen Regulation of the Cloned CA12 Enhancer Is Mediated By An Imperfect 
Estrogen-Response Element 
The in vivo recruitment of agonist-bound ERα and coactivator proteins, and 
histone modifications associated with transactivation, suggest that the identified region 
~6 kb upstream of the TSS is an enhancer for the CA12 gene.  Sequence analysis of 
putative transcription factor binding sites revealed one imperfect ERE with a 1 bp 
mismatch at approximately -6047 (relative to TSS; Fig. 3.5A).  To understand the cis 
elements involved in recruiting ERα and facilitating transactivation of CA12, we cloned 
the approximately 6.9 kb fragment of genomic DNA containing the putative upstream 
enhancer spanning a region approximating the captured DNA fragments binding ERα 
(ChIP-PET experiment, Fig. 3.3B) to just upstream of the CA12 TSS (-6832 – +46, 
Chr15:61461083-61467960).   In addition, we also cloned a truncated 1.8 kb fragment 
approximating the overlapping ChIP-PET cluster of ERα binding fragments (-6832 – -
4999), and both full-length (-6832 – +46) and truncated (-6832 – -4999) genomic 
fragments were then subcloned into luciferase reporter vectors to assay putative estrogen 
responsiveness (Fig. 3.5A).   After transfection into MCF-7 cells and exposure to 10 nM 
E2 for 16 h, the full-length reporter was stimulated approximately 8x over vehicle-treated 
transfectants or empty vector (Fig. 3.5B).  In addition, the truncated reporter 
approximating the greatest overlap of ChIP-PET fragments (-6832 – -4999) was able to 
stimulate reporter activity upon treatment with E2 comparable to that of the full-length 
reporter (-6832 – +46; Fig. 3.5B), implying that the E2-responsive region is located in the 
far-upstream genomic region.   
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As noted above, the ER-binding region at ~ -6 kb has one imperfect ERE (Fig. 
3.5A), which seemed a likely putative cis-regulatory element to direct ERα-dependent 
transactivation.  To examine this, we mutated both the single consensus half-ERE (Mut. 
1.0), or both the consensus half-ERE and imperfect arm of the ERE (Mut. 1.1). As seen 
in Fig. 3.5A and 3.5B, mutation of either one or both arms of the ERE abolished the 
ability of E2 to stimulate the -6832 – -4999 reporter, strongly suggesting that ER 
regulation of the cloned CA12 enhancer is dependent on an imperfect (1 mismatch) ERE 
at -6047 relative to the TSS. 
The ER-binding Distal Enhancer Communicates With the Transcriptional Start Site of the 
CA12 Gene via Intra-Chromosomal Looping Upon Estrogen Treatment In Vivo  
The observed in vivo recruitment of E2-bound ER to a putative distal enhancer 
region, and the E2- and ERE-dependent activation of the cloned ER-binding enhancer in 
transiently-transfected MCF-7 cells together suggest that the E2-mediated stimulation of 
CA12 is via an ER-dependent upstream enhancer approximately 6 kb upstream from the 
CA12 gene.  To test the in vivo utilization of this enhancer, we employed chromosome 
conformation capture (3C) assays to examine the putative communication of the -6 kb 
enhancer and the CA12 proximal promoter.  Briefly, after 45 min of 10 nM E2 treatment, 
MCF-7 cells were fixed with formaldehyde and chromatin was isolated, digested with 
Mse I, and subjected to dilute intramolecular ligation before de-crosslinking, DNA 
isolation, and PCR amplification of DNA fragments of interest.  Chromatin regions 
which are in close proximity with each other at the time of fixation were interrogated 
using PCR primers complementary to genomic DNA from the enhancer or proximal 
promoter regions.  Specifically, primers were used in variable combinations to examine 
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the presence of enhancer DNA only, proximal promoter DNA only, or all possible DNA 
species only produced by intramolecular ligation of DNA derived from the respective 
enhancer and promoter regions after fixation and digestion (Fig. 3.6, top).   
As shown in Figure 3.6A (middle), we observed a ligase- and E2-dependent 780 
PCR product amplified using the “A” forward primer from the enhancer region and “F” 
reverse primer from the proximal promoter region of CA12 (Fig. 3.6A and 3.6B).  
Normally separated by approximately 6 kb, the DNA amplified in the resulting PCR 
fragment was purified, sequenced, and mapped via BLAT to the UCSC human genome 
browser, and resulting sequence analysis indicated the E2- and ligase-dependent product 
was derived from both CA12 enhancer and promoter regions (Fig. 3.6A, bottom).  The 
estrogen-enhanced communication of the distal enhancer and proximal promoter in the 
3C assay strongly suggests that this ER-binding enhancer is functionally active in vivo.  
Taken together with the ChIP assays in which we did not observe appreciable in vivo 
recruitment of ERα or RNAPII in the intervening regions between the ER-binding 
enhancer and RNAPII-binding promoter, these 3C data suggest that the ER-binding 
enhancer transactivates the CA12 gene via intrachromosomal looping. 
Conservation of the CA12 Enhancer in Mammalian Genomes and of CA12 Regulation by 
Estrogen Receptor 
Analysis of the upstream region of CA12 by Vertebrate Multiz Alignment reveals 
a high degree of multi-species conservation within the newly-described, ERE-containing 
enhancer region (Fig. 3.6B, left).  Within the enhancer region (Fig. 3.6B), there is only 
one bp mismatch between the human and mouse 15-mer ERE.  To determine whether 
there is estrogen regulation of Car12, the mouse ortholog of the CA12 gene, 
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ovariectomized female mice were treated with E2 or vehicle, and uteri were collected at 4 
or 24 h post-injection (Fig. 3.6B, right).  At both time points examined, Car12 gene 
expression was robustly stimulated by E2.   These results provide strong evidence that the 
ER regulation of CA12 is both mechanistically and evolutionarily conserved.   
 
Discussion  
 Our studies reveal that the ER robustly up-regulates CA12 gene expression in 
breast cancer cells and that this transcriptional regulation is mediated by a hormone-
responsive enhancer located approximately 6.5 kb upstream of the start site of 
transcription of the CA12 gene. This marked regulation of CA12 by the ER may account 
for the strong coexpression of ER and CA12 that is observed in breast tumors.  
 Dynamic signal-specific assembly of transcription factors at enhancers is an 
increasingly recognized aspect of biological control of genes essential for developmental 
and hormonal response programs. Recent studies have suggested that the majority of 
estrogen-responsive genes may be under the control of ER-binding sites at a considerable 
distance (>5 kb) from the target RNA-coding loci (23, 31, 32), but there has been only 
limited evidence that they function as genomic regulatory elements for these relatively 
distant hormone-regulated genes. Here we describe regulation of the Carbonic Anhydrase 
XII (CA12) gene by agonist bound ER through a long-range distal enhancer that we have 
characterized through in vivo ChIP-scanning across  the CA12 genomic region and ChIP-
Paired End Ditag analysis, and by the ability of this element to strongly activate hormone 
dependent expression of a reporter.  This enhancer contains an imperfect estrogen 
response element which we show to be essential for its ER regulation through 
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mutagenesis and transfection studies.  Chromosome conformation capture (3C) and ChIP 
assays demonstrate a physical interaction between this distal enhancer and the CA12 
promoter in breast cancer cells upon E2 treatment, indicating a direct role for the 
enhancer in CA12 expression.   
 Associated with the recruitment of ligand-occupied ER to hormone-dependent 
enhancers is the recruitment of coregulators (2, 33, 34), some with histone acetyl 
transferase activity, resulting in distinct changes in histone acetylation status and 
chromatin conformational changes.  In the case of CA12 gene regulation, we observed 
markedly increased recruitment to the enhancer of the p160 coregulators, SRC2 and 
SRC3 that have HAT activity.  Of note, increased histone H4 acetylation status was 
observed not only at the enhancer and promoter regions, but also broadly throughout the 
upstream 5’-flanking region from the promoter to the enhancer and even at a more 
upstream region, suggesting that chromatin changes are effected over a broad region after 
receptor occupancy by ligand.  As expected, RNA polymerase recruitment was only 
observed at the promoter.   
 Selective estrogen receptor modulators (SERMs) such as tamoxifen and 
raloxifene, shown to be effective in both the prevention and the treatment of breast cancer 
(35, 36) often have mixed agonist-antagonist activities on estrogen-regulated genes in 
breast cancer (26, 37, 38).  Tamoxifen was a weak stimulator of CA12 RNA and protein 
expression compared to E2.  In keeping with this, tamoxifen was less effective in 
increasing recruitment of ER to the enhancer, in recruiting RNA polymerase II to the 
CA12 promoter, and in augmenting the acetylation of histone H4.  As observed 
previously for estrogen-regulated gene expression by SERMs (29), tamoxifen did not 
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recruit the SRC coregulators, suggesting that other coregulators are likely involved in 
eliciting the weak agonistic activity of tamoxifen on this gene.   
 Interestingly, the distal enhancer element displays synteny with the homologous 
mouse genomic sequence, and its robust stimulation by E2 in the mouse uterus highlights 
that ER regulation of CA12 is mechanistically and evolutionarily conserved.  Other 
approaches, including bioinformatic coupled with genome-wide nuclear receptor binding 
site analyses, have suggested the likely conservation of gene regulatory mechanisms at 
other estrogen responsive genes across mammalian species (23, 32). 
 Gene regulation by long distance enhancers has been observed recently for other 
nuclear receptors, such as the androgen receptor in its control of the prostate-specific 
antigen (PSA) gene (39).  Also, recent reports have documented long distance enhancer 
regulation of GREB1 (gene regulated in breast cancer- 1), encoding a protein with an 
unknown function but suggested to contribute to the enhancement of proliferation of 
MCF-7 cells by E2 (40, 41).  In the case of GREB1, its stimulation by E2 is mediated by 
the binding of ER to three consensus EREs spread over approximately 20 kb of upstream 
flanking sequences (41, 42).   
 CA12 is a membrane zinc metalloenzyme that is present in a variety of normal 
tissues but is overexpressed in some cancers (13, 20, 21, 43-47).  In MCF-7 cells, we find 
that CA12 and CA9 are the only carbonic anhydrases that are expressed (DH Barnett and 
BS Katzenellenbogen, data not shown).  CA12 and CA9 mRNA and protein levels are 
stimulated by hypoxia in a variety of cancer cell lines, and their expression is down-
regulated by return to normoxia (13, 17, 47, 48).  Of note, however, we find that only 
CA12, and not CA9, is regulated by estrogen, and likewise, only CA12, and not CA9, 
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exhibits a strong positive correlation with ER expression in breast tumors (4, 19).  The 
activity of CA12 as a metalloenzyme, catalyzing the reversible hydration of carbon 
dioxide to form bicarbonate, is likely involved in modulating a variety of physiological 
processes including transport of carbon dioxide and other solutes, as well as acidification 
of microenvironments that can modulate the tumor malignant phenotype (16, 49, 50).  
That CA12 expression in breast tumors is associated with lower grade disease, positive 
ERα status, and lower relapse rates and better overall patient survival (20-22), suggests 
that the estrogen receptor regulation of CA12 expression may be an important parameter 
in this more optimal breast tumor phenotype. 
 Gene expression microarray profiling has documented that ERα is a master 
transcriptional regulator of the phenotype and behavior of approximately 70 percent of 
human breast cancers, and that the gene expression signatures in ERα-positive and ERα-
negative breast tumors are profoundly different (5-7, 19). CA12 is one of the genes 
whose expression is most highly correlated with ERα in breast cancer.  In fact, for 
comparison with the correlations shown in Fig. 3.2D for CA12 and ERα, we examined 
the association of ERα with progesterone receptor, a well-characterized ER target gene 
and useful clinical marker, in the same three studies of primary breast cancer gene 
expression.  Interestingly, the correlation of progesterone receptor with ER in the studies 
by van de Vijer (0.296), Miller (0.287), and Wang (0.374) is considerably less than the 
correlation of CA12 with ER in the same data sets (Fig. 3.2D), highlighting the robust 
association of CA12 and ER expression.  Our findings reveal a transcriptional regulatory 
mechanism that likely underlies this robust coexpression of CA12 and ERα in human 
breast cancers. In addition, our findings imply that involvement of long distance 
82
enhancers in regulation of estrogen-responsive genes in breast cancer may be more 
frequent than previously appreciated.  
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Figures 
 
 
 
Figure 3.1.  Various Estrogen Receptor Ligands Increase CA12 Levels in Breast 
Cancer Cells 
(A) CA12 mRNA is induced in a time-dependent manner by estradiol (E2) in ERα 
-expressing MCF-7 and T47D breast cancer cells. Cells were treated with 10nM E2 for 0-
48 h.  RNA was isolated, reverse transcribed, and cDNA measured by quantitative PCR 
(qPCR) using primers for CA12 and internal control 36B4 mRNA.  (B) CA12 protein 
levels are induced by E2 in a time dependent manner.  MCF-7 cells were treated with 10 
nM E2 for 0-24 h and total cellular lysates were used for CA12 immunoblotting.  (C) 
CA12 mRNA is induced by ER agonists.  MCF-7 cells were treated for 8 h with vehicle 
(0.1% EtOH) or with intracellular receptor ligands E2 (10 nM), fulvestrant (ICI 182,780, 
Ful; 1 uM),  Ful + E2, trans-hydroxytamoxifen (Tam; 100 nM), Ful + Tam, raloxifene  
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Figure 3.1. (Cont.) 
(Ral; 100 nM), Ful + Ral, dihydrotestosterone (DHT; 10nM), hydrocortisone (HC, 10 
nM), or medroxyprogesterone acetate (MPA; 10 nM).  Cells were then harvested and  
qRT-PCR performed as above.  (D) E2 and the SERMs induce CA12.  MCF-7 cells were 
treated for 8 h with 10nM E2, 100 nM Tam, or 100 nM Ral and CA12 protein levels 
assessed by immunoblotting as above.    
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Figure 3.2.  E2 Stimulation of CA12 Gene Expression is Sensitive to Actinomycin D 
and Fulvestrant (ICI 182,780), but not Cycloheximide, and requires ERα. Strong 
Association of CA12 and ERα in breast tumor data sets.  
(A) CA12 mRNA induction by E2 is blocked by pre-treatment with the transcriptional 
inhibitor actinomycin D, or the pure ER antagonist fulvestrant, but not the translational 
inhibitor cycloheximide.  MCF-7 cells were pre-treated for 60 min. with 0.1% DMSO,  
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Figure 3.2. (Cont.) 
1 uM Ful, 10 ug/mL cycloheximide (CHX), or 5 uM Actinomycin D (Act.D) and then 
0.1% EtOH or 10 nM E2 was added for 2 h.  qRT-PCR for CA12 mRNA was performed.  
(B) ER antagonist Fulvestrant blocks E2 stimulation of CA12.  MCF-7 cells were treated 
for 8 h with 0.1% EtOH, 10 nM E2, 1 uM Ful, or both E2 and Ful prior to cell lysis and 
immunoblotting for CA12.  (C) CA12 mRNA induction is ER-dependent.  MCF-7 cells 
were transfected with 5 nM siControl or 5 nM siRNA against ERα for 72 h.  Cells were 
then treated for 4 h with 0.1% EtOH, 10 nM E2, 100 nM Tam, or 100 nM Ral prior to 
RNA isolation and qRT-PCR analysis.  (D) Scatter plots and correlation between CA12 
and ERα RNA expression in breast tumors from the indicated studies. The plots were 
generated from the Oncomine Database. The x and y axes represent fold change in 
expression for CA12 and ERα (ESR1), respectively.  
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Figure 3.3.  E2-Occupied ER is Recruited to a Distal Region 6.5 kb Upstream of the 
CA12 Transcription Start Site In Vivo.  
(A) Whole-genome ERα binding sites were mapped in MCF-7 cells treated with 10 nM 
E2 for 45 min using ChIP-PET strategy (23) and mapped to the CA12 genomic region in 
the UCSC Genome Browser (Hg17).  A singular ChIP-PET cluster approximately 6 kb 5’ 
to CA12 transcriptional start site (top) is shown, with a higher resolution map with 
individual fragments indicated (bottom).  (B)  and (C)  ChIP scanning of the CA12  
88
Figure 3.3. (Cont.) 
genomic region in vivo validates ChIP-PET identification of putative CA12 enhancer.  
(B)  A schematic representation of Chromosome 15 and primer set locations (A-L) 
immediately 5’ to the CA12 transcriptional start site.  (C)  E2-occupied ERα is recruited 
to an upstream region ca. 6 kb 5’ to the CA12 gene.  MCF-7 cells were treated for 45 min 
with control 0.1% EtOH or 10 nM E2, subjected to ERα ChIP, and immunoprecipitated 
DNA amplified using PCR primers as denoted in (B) and recovered DNA represented as 
percent of input.  
 
89
  
 
Figure 3.4.   
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Figure 3.4. (Cont.) 
E2- and SERM-Induced Transcription Factor Recruitment and Chromatin 
Modifications to the CA12 Genomic Region In Vivo 
E2- and Tam-treated MCF-7 cells were examined for recruitment of ERα, RNA 
Polymerase II, SRC-2, and SRC-3 binding and acetylated H4 modifications within the 
CA12 genomic region using various primer sets at denoted positions (Top, schematic).  
Immunoprecipitated DNA, expressed as % input, from experiments using specific 
indicated antibodies (left) and amplified using primer sets as denoted above.  
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Figure 3.5.  Estrogen Regulation of the Cloned CA12 Enhancer Is Mediated By An 
Imperfect Estrogen-Response Element  
 (A)  A schematic representation indicates genomic regions identified as binding ERα by 
ChIP scanning and ChIP-PET analysis (ChIP-PET moPET5) and cloned genomic regions 
used for cis-element reporter assays.  Indicated at the open triangle position is the wild 
type imperfect ERE with sequence shown above (above, left), as well as mutated 
sequences used (above, right;  mutated nucleotides underlined and bases differing from 
wild type in lower case).   
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Figure 3.5. (Cont.) 
(B)  Cloned CA12 enhancer reporter activity is dependent on an imperfect ERE.  
Indicated full length, truncated, mutated, and empty reporter plasmids (left, 1 μg ea.) 
were cotransfected with pRL-SV40 (25 ng) into MCF-7 cells in 24-well plates.  At 24 h 
after transfection, cells were treated for 16 h with 0.1% EtOH or 10 nM E2, lysed, and 
assayed for Firefly and Renilla luciferase activities (right).    Open triangle indicates wild 
type imperfect ERE ca. 6 kb upstream of CA12 TSS, grey triangle indicates mutant 1.0, 
and black triangle indicates mutant 1.1. 
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Figure 3.6.   
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Figure 3.6. (Cont.) 
ER-binding Distal Enhancer Communicates With the Transcriptional Start Site of 
the CA12 Gene via Intra-chromosomal Looping Upon Estrogen Treatment In Vivo, 
and Enhancer Shows Conservation Between Humans and Mice.   (A)  Top, 
Schematic of the CA12 genomic region, Mse I restriction enzyme cut sites, and primer 
positions for chromosome conformation capture (3C).  Middle, CA12 enhancer and 
promoter show enhanced communication upon E2 treatment in MCF-7 cells in vivo.  
Cells were treated for 45 min with 0.1% EtOH or 10 nM E2, cross-linked, and subjected 
to 3C analysis using indicated primer pairs.  Bottom, E2- and ligase-dependent 3C PCR 
product was purified, sequenced, and mapped to the human genome by UCSC BLAT 
indicating proximal and distal DNA communication.  (B) Vertebrate Multiz Alignment 
shows conservation of the -6 kb CA12 ERE-containing enhancer region.  (C)  Car12 
mRNA is induced by E2 in the mouse uterus.  Eight week-old female mice were 
ovariectomized and at 16 days post-ovariectomy, they were injected with vehicle or E2.  
Uteri were collected 4 or 24 h later and total RNA was isolated and subjected to qRT-
PCR for Car12 mRNA. 
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AWARDS and HONORS 
 
Named to “Teachers Ranked as Excellent" for University of Illinois College of Medicine (2008) 
Carle Foundation / University of Illinois at Urbana-Champaign Thomas A. Buetow Memorial Grant (2007) 
The Endocrine Society Fellows and Students Workshop Award (2007) 
NIH Reproductive Biology Pre-Doctoral Training Fellowship (T32HD07028, 2004-2006) 
The Endocrine Society Travel Grant Award for Exceptional Research (2004) 
University of Illinois at Urbana-Champaign Graduate College Travel Grant (2004) 
NIH Reproductive Biology Training Grant Travel Award (2003) 
NIH Toxicology Pre-Doctoral Training Fellowship (T32ES07326, 2002-2004) 
Best Poster Award, 92nd Annual Meeting of the American Urological Association (1997) 
Colorado College Representative to West Coast Undergraduate Research Conference in Biological 
Sciences (1995) 
Howard Hughes Medical Institute Undergraduate Research Fellowship (Summer and Fall 1994) 
The Colorado College Dean’s List (1992-1993, 1994-1995) 
 
PROFESSIONAL and COMMUNITY SERVICE 
  
Member, Psychiatry Clerkship Curriculum Review Committee                 2009  
University of Illinois College of Medicine, Urbana-Champaign 
Member, Medicine and Society Clerkship Curriculum Review Committee         2009 
University of Illinois College of Medicine, Urbana-Champaign 
Chairperson, American Cancer Society Man-to-Man Prostate Cancer Support Group          2008 – Present 
Institutional Representative, American Physician Scientists Association           2007 – 2009 
Student Member, HeRMES Student-Operated Free Clinic, Champaign-Urbana, IL      2007 – Present 
Chair (2005) and Vice-Chair (2006 – Present), Physicians for Social Responsibility      2005 – Present 
University of Illinois College of Medicine, Urbana-Champaign 
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Oral Session Chairperson, 9th Biennial Allerton Reproductive Biology Conference        2005 
Trainee Liaison, NIH Reproductive Biology Training Program            2004 – 2006 
University of Illinois College of Medicine, Urbana-Champaign 
Chairperson, Medical Scholars Program Advisory Committee            2001 – 2003 
University of Illinois College of Medicine, Urbana-Champaign 
    
TEACHING EXPERIENCE 
  
 Medical Pharmacology, University of Illinois College of Medicine at Urbana-Champaign    Fall 2008, 2009  
Medical Histology, University of Illinois College of Medicine at Urbana-Champaign         Fall, Spring 2008 
Medical Neuroscience, University of Illinois College of Medicine at Urbana-Champaign           Spring 2008 
 
PROFESSIONAL SOCIETIES 
  
 American Physician Scientists Association             2006 
The American Society for Cell Biology, Student Member                         2005 
 The Endocrine Society, Student Associate                           2003 
 American Association for the Advancement of Science, Student Member                       2002 
 Physicians for Social Responsibility             2001 
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